Report Sections

See All Reports

  • drug2029: Ivermectin
  • Placebo (543) Hydroxychloroquine (100) Standard of Care (41) Azithromycin (38) Tocilizumab (37) Questionnaire (33) Placebo oral tablet (31) Convalescent Plasma (28) Remdesivir (28) Standard of care (26) Favipiravir (23) No intervention (23) Convalescent plasma (22) Ivermectin (22) Placebos (17) Nitazoxanide (15) Survey (15) placebo (15) Enoxaparin (14) Methylprednisolone (14) Vitamin C (14) Control (13) Colchicine (12) Hydroxychloroquine Sulfate (12) Blood sample (11) Lopinavir/ritonavir (10) Questionnaires (10) Ruxolitinib (10) Saline (10) blood sample (10) Anakinra (9) Dexamethasone (9) Losartan (9) Standard care (9) Usual Care (9) Vitamin D (9) no intervention (9) Camostat Mesilate (8) Nasopharyngeal swab (8) Questionnaire Administration (8) Zinc (8) Baricitinib (7) Chloroquine (7) Oseltamivir (7) Saliva collection (7) Standard treatment (7) questionnaire (7) survey (7) Blood sampling (6) Clazakizumab (6) DAS181 (6) LY3819253 (6) Normal Saline (6) Normal saline (6) Prednisone (6) Vitamin D3 (6) blood sampling (6) convalescent plasma (6) Ad26.COV2.S (5) Best Practice (5) COVID-19 Convalescent Plasma (5) COVID-19 convalescent plasma (5) Cyclosporine (5) Doxycycline (5) Hydroxychloroquine (HCQ) (5) Lopinavir / Ritonavir (5) Lung ultrasound (5) Mepolizumab (5) Midazolam (5) Online Survey (5) Quality-of-Life Assessment (5) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (5) Rivaroxaban (5) Sarilumab (5) Standard Medical Treatment (5) Standard of Care (SOC) (5) UC-MSCs (5) hydroxychloroquine (5) questionnaire assesment (5) AZD1222 (4) Acalabrutinib (4) Alirocumab (4) Ascorbic Acid (4) Aspirin (4) Association atezolizumab + BDB001 + RT (4) BCG Vaccine (4) Blood draw (4) COVID-19 (4) Cholecalciferol (4) Colchicine Tablets (4) Dapagliflozin (4) Data collection (4) Evolocumab (4) Famotidine (4) Gam-COVID-Vac (4) HCQ (4) Hydrocortisone (4) Interferon Beta-1A (4) Interferon beta-1a (4) Lopinavir/Ritonavir (4) Matching placebo (4) Mavrilimumab (4) Melatonin (4) Methotrexate (4) Nitric Oxide (4) Nivolumab (4) Observational (4) Online questionnaire (4) Online survey (4) Ontamalimab (4) Opaganib (4) Oxygen (4) Peginterferon beta-1a (4) Placebo Administration (4) Povidone-Iodine (4) Presatovir (4) Prone position (4) Prone positioning (4) RLS-0071 (4) Reslizumab (4) Ribavirin (4) Rifampin (4) Rosuvastatin (4) SARS-CoV-2 (4) Standard Care (4) Telemedicine (4) Telerehabilitation (4) Usual care (4) Yoga (4) anti-SARS-CoV-2 convalescent plasma (4) standard care (4) 3D Telemedicine (3) ACE inhibitor (3) AG0302-COVID19 (3) Abatacept (3) Allopurinol (3) Anti-SARS-CoV2 Serology (3) Apremilast (3) BAY1817080 (3) BCG vaccine (3) BI 764198 (3) BI 894999 (3) BNT162b1 (3) BNT162b2 (3) Best Supportive Care (3) Biospecimen Collection (3) COVID-19 RT-PCR (3) COViage (3) Chloroquine or Hydroxychloroquine (3) Chloroquine phosphate (3) Clinical data (3) Clopidogrel (3) Cognitive Behavioral Therapy (3) Control group (3) DWRX2003 (3) ECG (3) EIDD-2801 (3) Echocardiography (3) Eltrombopag (3) Exercise (3) Heparin (3) Interferon Beta-1B (3) Interview (3) Itraconazole (3) LY3832479 (3) Lenzilumab (3) Mesenchymal Stromal Cells (3) Mesenchymal stromal cells (3) Mindfulness (3) Nafamostat Mesilate (3) Naltrexone (3) Nitric Oxide Gas (3) No Intervention (3) No intervention, observational study (3) Observation (3) Pentoxifylline (3) Phase 2 (3) Placebo oral capsule (3) Plasma (3) Probiotic (3) Prone Positioning (3) Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health (3) REGN10933+REGN10987 combination therapy (3) RT-PCR (3) Ravulizumab (3) Relamorelin (3) Remestemcel-L (3) SARS-CoV-2 convalescent plasma (3) Saline Placebo (3) Sargramostim (3) Selinexor (3) Serological test (3) Siltuximab (3) SnPP Protoporphyrin plus Sunlight exposure (3) Standard of care (SOC) (3) Supportive Care (3) Survey Administration (3) Suspension of heat killed (autoclaved) Mycobacterium w (3) Telmisartan (3) VPM1002 (3) Verinurad (3) Vitamin Super B-Complex (3) blood donation SMS (3) exhaled breath sampling (3) observational (3) placebo for risankizumab (3) risankizumab IV (3) risankizumab SC (3) self-administered questionnaire (3) standard of care (3) standard therapy (3) 0.9% Saline (2) 100 mg/mL Virazole (2) 2D Telemedicine (2) 50 mg/mL Virazole (2) AG0301-COVID19 (2) ARB (2) ATI-450 (2) AZD5718 (2) Abidol hydrochloride (2) Acalabrutinib Treatment A (2) Acalabrutinib Treatment B (2) Acalabrutinib Treatment C (2) Aeonose (2) Aerobic Exercise Training (2) Allocetra-OTS (2) Ampion (2) Angiotensin 1-7 (2) Angiotensin II (2) Angiotensin converting enzyme inhibitor (2) Antibiotics (2) Arbidol (2) Assessment of behavioral response to emotional stimulation (2) Assessment of work-related stress (2) Association atezolizumab + BDB001+ RT (2) Atorvastatin (2) Attention Placebo (2) Ayurveda (2) Azithromycin Tablets (2) BCG-Denmark (2) BI 474121 (2) BIIB091 (2) Bacille Calmette-Guérin (BCG) (2) Baloxavir Marboxil (2) Baricitinib Oral Tablet (2) Bemiparin (2) Bevacizumab Injection (2) Bicalutamide 150 Mg Oral Tablet (2) Biological data (2) Biological sample collection (2) Blood samples (2) Blood test (2) Blood tests (2) Breath Biopsy face masks with removable filters and fitted PVA strip (2) Brequinar (2) Brief cognitive intervention (2) Bucillamine (2) CELLECTRA® 2000 (2) CFTR Modulators (2) COVID Convalescent Plasma (2) COVID-19 Serology (2) COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection (2) COVID-19 pandemic (2) COVID-19 patients (2) CT-P59 (2) CT-Scan (2) CYT107 (2) Cabotegravir Tablets (2) Camostat Mesylate (2) Canakinumab (2) Candin (2) Cannabidiol (2) Carboplatin (2) Cardiac and electrodermal recordings (2) ChAdOx1 MERS (2) ChAdOx1 nCoV-19 (2) Chemotherapy (2) Chloroquine Sulfate (2) Chloroquine or hydroxychloroquine (2) Clinical Examination (2) Clinical assessment (2) Convalescent COVID 19 Plasma (2) Convalescent Plasma (CP) (2) Convalescent Plasma (anti-SARS-CoV-2 plasma) (2) Convalescent Plasma Transfusion (2) Conventional treatment (2) Corticosteroid (2) Daclatasvir (2) Data Collection (2) Data record (2) Deferoxamine (2) Dexamethasone injection (2) Diagnostic test (2) Disulfiram (2) Dornase Alfa Inhalation Solution [Pulmozyme] (2) Duvelisib (2) EC-18 (2) EDP1815 (2) EXO 1 inhalation (2) EXO 2 inhalation (2) Early-Dexamethasone (2) Ebselen (2) Eculizumab (2) Electronic questionnaire (2) Enhanced Usual Care (2) Enoxaparin 40 Mg/0.4 mL Injectable Solution (2) Ensifentrine (2) Exebacase (2) Exercise program (2) Exercise training (2) Exposure (2) Expressive writing (2) Famotidine 20 MG (2) Favipiravir Placebo (2) Fiberoptic Endoscopic Evaluation of Swallowing (2) Fisetin (2) Flow cytometric analysis (2) Fluoxetine (2) Follow up (2) Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale (2) GLPG3970 (2) GLS-5300 (2) GSK3640254 (2) Guduchi Ghan Vati (2) HB-adMSCs (2) HFNC (2) Hepatitis A vaccine (2) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Home exercise (2) Human immunoglobulin (2) Hydroxychloroquine + azithromycin (2) Hydroxychloroquine - Weekly Dosing (2) Hydroxychloroquine 200 Mg Oral Tablet (2) Hydroxychloroquine Sulfate 200 MG (2) Hydroxychloroquine Sulfate 200 MG [Plaquenil] (2) Hydroxychloroquine Sulfate Loading Dose (2) Hydroxychloroquine Sulfate Regular dose (2) Hydroxychloroquine Sulfate Tablets (2) Hydroxychloroquine and Azithromycin (2) Hypothermia (2) ICU treatment (2) IMU-838 (2) INO-4800 (2) IVIG (2) Ibrutinib (2) Icosapent ethyl (2) Inactivated SARS-CoV-2 Vaccine (Vero cell) (2) Infliximab (2) Interferon beta-1b (2) Interleukin-7 (2) Iodine Complex (2) Ivermectin Oral Product (2) Ivermectin Pill (2) Ivermectin and Doxycycline (2) Ixazomib (2) KB109 + Self Supportive Care (SSC) (2) Ketogenic diet (2) L-ascorbic acid (2) Lanadelumab (2) Leflunomide (2) Leronlimab (700mg) (2) Lopinavir-Ritonavir (2) Low Dose Radiation Therapy (2) Low Dose Radiotherapy (2) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Low molecular weight heparin (2) M5049 (2) MEDI3506 (2) MSC (2) MagPro X100 Stimulator, B70 Fluid-Cooled Coil (2) Matched Placebo (2) Meaning Centered Psychotherapy for Latinos (2) Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients (2) Meditation (1 x 20-minute guided audio training) (2) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Meplazumab for Injection (2) Metformin (2) Methylprednisolone Sodium Succinate (2) Mindfulness Based Intervention (2) Mobocertinib (2) Molnupiravir (2) Moxifloxacin (2) N-Acetyl cysteine (2) N-acetylcysteine (2) NORS (Nitric Oxide Releasing Solution) (2) Nasal swab (2) Nasopharyngeal swabs (2) Neuromuscular Blocking Agents (2) Niclosamide (2) Niclosamide Oral Tablet (2) Nigella Sativa / Black Cumin (2) Nitrogen gas (2) Observational study (2) Olokizumab 64 mg (2) Other (2) PLACEBO (2) PLX-PAD (2) PUL-042 Inhalation Solution (2) Paracetamol (2) Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances (2) Peginterferon Lambda-1A (2) Pembrolizumab (2) Peripheral blood draw (2) Phase 1 (2) Phone call (2) Physiotherapy (2) Placebo Comparator (2) Placebo capsules (2) Placebo inhalation (2) Placebo on a 0- and 28-day schedule (2) Postcard (2) Povidone-Iodine Nasal Spray and Gargle (2) Pozelimab (2) Practice details (2) Prazosin (2) Pre-assessment questionnaire (2) Psychoeducation (2) Pulmozyme (2) RECOP unit patient (2) RLF-100 (aviptadil) (2) RO6889450 (2) RTB101 (2) Rabeprazole (2) Radiation therapy (2) Radiotherapy (2) Recombinant new coronavirus vaccine (CHO cell) low-dose group (2) Recombinant new coronavirus vaccine (CHO cells) high-dose group (2) Recombinant new coronavirus vaccine (CHO cells) placebo group (2) Remdesivir placebo (2) Rifampicin (2) Rilpivirine Tablets (2) Risankizumab (2) Rituximab (2) Routine care for COVID-19 patients (2) Ruxolitinib Oral Tablet (2) SAB-185 (2) SARS-CoV-2 diagnostic rapid test (2) SARS-CoV-2 rS/Matrix-M1 Adjuvant (2) SARS-Cov2 testing (2) SEL-212A (2) SEL-212B (2) SOC + Placebo (2) Saline solution (2) Saliva sample collection (2) Sample collection (2) Sampling (2) Self Supportive Care (SSC) Alone (2) Seraph 100 (2) Serology test for COVID-19 (2) Serum testing (2) Sevoflurane (2) Simple cognitive task intervention (2) Simvastatin (2) Single Dose of Hydroxychloroquine (2) Sirolimus (2) SivoMixx (200 billion) (2) Spirometry (2) Standard Therapy (2) Standard of Care (SoC) (2) Standard of care treatment (2) Stellate Ganglion Block (2) T3011 (2) TD-0903 (2) Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. (2) Telehealth (2) Telisotuzumab vedotin (2) Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (2) Tezepelumab (2) Therapeutic Plasma Exchange (2) Therapeutic anticoagulation (2) Throat swab (2) Thymalfasin (2) Tildrakizumab (2) Tocilizumab (TCZ) (2) Tocilizumab Injection (2) Tofacitinib (2) Tofacitinib 10 mg (2) Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit (2) Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of placebo at the schedule of day 0,28 (2) Unfractionated heparin (2) Virtual Reality (2) Volatile Organic Compounds analysis (2) Volitional help sheet (2) Vonoprazan (2) basic treatment (2) blood draw (2) blood samples (2) blood test (2) mRNA-1273 (2) nasopharyngeal swab (2) other (2) oxygen therapy (2) pregnant women with laboratory-confirmed 2019-n-CoV (2) prone position (2) retrospective analysis (2) rhTPO (2) serology (2) survey work (2) tabelecleucel (2) tocilizumab (2) unfractionated Heparin (2) venous ultrasound (2) vv-ECMO + cytokine adsorption (Cytosorb adsorber) (2) vv-ECMO only (no cytokine adsorption) (2) "Calm" is a mindfulness meditation mobile app (1) "Vernonia amygdalina" (1) (Standard of Care) SoC (1) - Synthetic anti-malarial drugs (1) 0.075% Cetylpyridinium Chloride (1) 0.12% Chlorhexidine Gluconate (1) 0.12% Chlorhexidine Gluconate Mouth Rinse (1) 0.12% Chlorhexidine oral/nasal rinse (1) 0.5% Povidone Iodine (1) 0.5% Povidone/Iodine oral/nasal rinse (1) 0.9% Normal Saline (1) 0.9% Sodium Chloride (Placebo) (1) 0.9% Sodium-chloride (1) 0.9% saline (1) 0.9% sodium chloride (normal saline) (1) 0.9%NaCl (1) 0.9%sodium chloride (1) 1% Hydrogen Peroxide (1) 1% w/v Povidone-iodide (1) 1. Characterize the immune response after infection with SARS-CoV-2 (1) 1.5-2% w/v Hydrogen Peroxide (1) 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse (1) 11C-ER176 (1) 12 weeks of bicycle exercise (1) 12-page health warning leaflet (1) 12-week FMS Intervention (1) 14C-lazertinib (1) 150 ppm Nitric Oxide delivered through LungFit Delivery System (1) 18F-DX600 PET/CT (1) 18F-Florbetaben (1) 18F-GP1 PET CT (1) 18F-MK-6240 (1) 18F-αvβ6-BP (1) 1: ILT101 (1) 1: Naproxen (1) 1: Prone positioning (1) 1: Usual practice (1) 1: discontinuation of RAS blocker therapy (1) 1D (1) 20 Mg Prednisone for 14 days (1) 20 mg MitoQ (1) 2019-nCoV IgG/IgM Rapid Test Cassette (1) 2019-nCoV PCR (1) 21% Ethanol plus essential oils (1) 25-OH cholecalciferol (1) 2: No instruction regarding positioning (1) 2: Placebo Comparator (1) 2: Standard of care (1) 2: Usual practice + SYMBICORT RAPIHALER (1) 2: continuation of RAS blocker therapy (1) 3 Wishes Project (1) 30 Gy over 3 weeks (1) 300 mg of omega3-FA (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) (1) 38 questions questionnaire (1) 38-questions questionnaire (1) 3D (1) 40-Steps-test (1) 40mg of MitoQ (1) 40ml blood sample (1) 4Plants/Azythromycin (1) 5-ALA-Phosphate + SFC (5-ALA + SFC) (1) 50 Gy Radiation Therapy (1) 55 Gy Radiation Therapy (1) 5Fluorouracil (1) 6 minute walk test (1) 60 Gy Radiation Therapy (1) 68Ga-DX600 PET/CT (1) 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) (1) 80 ppm Nitric Oxide delivered through LungFit Delivery System (1) A $10 Survey Incentive (1) A $20 Survey Incentive (1) A short video intervention (1) A vignette intervention (1) AAZ Covid-19 rapid test (1) ABC/3TC (1) ABPM (1) ABTL0812 (1) ABX464 (1) ACE Inhibitors and Calcium Channel Blockers (1) ACE inhibitor, angiotensin receptor blocker (1) ACEI (1) ACEI/ARB (1) ACEIs (1) ACT-1014-6470 (1) ACT-20-CM (1) ACT-20-MSC (1) ACT-541478 10 mg (1) ACT-541478 100 mg (1) ACT-541478 1000 mg (1) ACT-541478 30 mg (1) ACT-541478 300 mg (1) ACT-541478 dose E1 (1) ACT-541478 high or low dose (or placebo) (1) ADAM Sensor (1) ADCT-301 (1) ADM03820 (1) AI model (1) AIRVO (1) AK119 (1) ALLOCETRA-OTS (1) ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS (1) ALX148 (1) ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen) (1) AMA Acknowledgement Drug Pricing (1) AMY-101 (1) AN69-Oxiris (1) AN69-Standard (1) APL-9 (1) APPS (1) ARALAST NP (1) ARBIDOL 100 MG KAPSUL (1) ARBOX (1) ARBs and/or ACE inhibitors (1) ARCT-021 Dose 1 (1) ARCT-021 Dose 2 (1) ARCT-021 Dose 3 (1) ARCT-021 Dose 4 (1) ARCT-021 Dose Regimen 1 (1) ARCT-021 Dose Regimen 2 (1) ARDSNet (1) ARFC mask (1) ARGX-117 (1) ARGX-117 + rHuPH20 (1) ASC09/ritonavir group (1) ASC09F+Oseltamivir (1) ASP0367 (1) ASP2390 (1) ASP7317 (1) ASP8374 (1) ASSIST (1) ASTX660 (1) AT-001 (1) AT-527 (1) ATAFENOVIR 200 MG KAPSUL (1) ATI-1777 (1) ATYR1923 1 mg/kg (1) ATYR1923 3 mg/kg (1) AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong (1) AUP1602-C (1) AV-COVID-19 (1) AVIGAN (1) AVIGAN 200 MG Film Tablets (1) AVIGAN 200 mg FT (1) AVIGAN 200 mg Film Tablets (1) AVM0703 (1) AVP 4 (1) AVP I (1) AVP II (1) AWARD advice (1) AWARD plus COVID-specific advice (1) AZD1390 (1) AZD1656 (1) AZD2693 (1) AZD7442 (1) AZD8154 Monodose DPI presented in capsules (1) AZD8154 Placebo Monodose DPI presented in capsules (1) AZD8154 nebuliser (1) AZD9567 (1) AZD9833 Oral Solution (1) AZD9833 film-coated tablet A Dose 1 (1) AZD9833 film-coated tablet A Dose 2 (1) AZD9833 film-coated tablet B Dose 1 (1) AZD9833 film-coated tablet B Dose 2 (1) AZD9977 (1) Abdominal ultrasound (1) Abidol Hydrochloride combined with Interferon atomization (1) Abiraterone Acetate (1) Abivertinib (1) Absolute Pro LL stent (1) Acacia Senegal (1) Acalabrutinib Treatment D (1) Acceptability questionnaire (1) Access to training facility (1) Accuchek Inform II platform (1) Acetazolamide + supplemental oxygen + PAP therapy (1) Acetylsalicylic acid (1) Acknowledgement Racial Injustice AMA (1) Acthar Gel (1) Actigraph (1) Active COVID-19 disease (1) Active Choice (1) Active Comparator (1) Active Comparator: Control (1) Active Control (1) Active PBMT/sMF (1) Active control condition (1) Active control:Healthy Living (1) Active nudge text feedback (1) Activity (1) Activity plan to break up sitting time (1) Acyclovir (1) Ad26.ZEBOV (1) Ad5-nCoV (1) Ad5FGF-4 (1) Adalimumab (1) Additional and minimal collection of products of the human body carried out during a sample for standard of care (1) Additional biological samples (1) Adenosine (1) Adenovirus Type-5 Vectored COVID-19 Vaccine (1) AdimrSC-2f (1) Administration of Equine immunoglobulin anti SARS-CoV-2 (1) Admission to ICU for COVID-19 (1) Adsorbed COVID-19 (inactivated) Vaccine (1) Aerobic training (1) Aerolized Hydroxychloroquine Sulfate (1) Aerosol Box (1) Aerosol-reducing Mask (1) Aerosolized 13 cis retinoic acid (1) Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg (1) Aerosolized All trans retinoic acid (1) Aerosolized All-Trans Retinoic acid plus oral Tamoxifen (1) Aerosolized Isotretinoin plus Tamoxifen (1) African American Sender Acknowledgement (1) African American Sender in Informational Videos. (1) After COVID-19 Pandemic (1) AirGo Respiratory Monitor (1) Airwave Oscillometry (1) Airway pressure release ventilation (1) Albendazole (1) Albuterol - Control (1) Albuterol - Experimental (1) Alcohol (1) Alcohol brief intervention (1) Alexa Amazon (1) Alferon LDO (1) Algorithm-based recommendation (1) Alisporivir (1) AlloStim (1) Allogeneic NK transfer (1) Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells (1) Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (1) Almitrine (1) Alprazolam 1mg XR (1) Alteplase 100 MG [Activase] (1) Alteplase 50 MG [Activase] (1) Alternating face-to-face medical visits and video medical consultations (1) Aluminum adjuvant (1) Aluminum hydroxide (1) Aluminum hydroxide adjuvant (Alhydrogel®) (1) Alvelestat (1) Ambrisentan (1) Amiodarone (1) Amlodipine (1) Amlodipine 2.5 mg/indapamide 1.25 mg (1) Amoxicillin-clavulanate (1) An auto-questionnaire comprising three psychometric scales (1) Anakinra +/- Ruxolitinib (stages 2b/3) (1) Anakinra 100Mg/0.67Ml Inj Syringe (1) Anakinra 149 MG/ML Prefilled Syringe [Kineret] (1) Anakinra Prefilled Syringe (1) Anakinra alone (stages 2b/3) (1) Anakinra and Ruxolitinib (Advanced stage 3) (1) Anakinra and Ruxolitinib (overcome stage 3) (1) Anakinra and Zinc (1) Anakinra plus oSOC (1) Analogs, Prostaglandin E1 (1) Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage. (1) Anatomic Pulmonary Resection (1) Anger message (1) Angiography (1) Angiography scanner (1) Angiotensin II Receptor Blockers (1) Angiotensin Receptor Blockers (1) Angiotensin receptor blocker (1) Angiotensin-(1-7) (1) Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB) (1) Anluohuaxian (1) Anthocyanins (1) Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients (1) Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients (1) Anti- SARS-CoV-2 Plasma (1) Anti-COVID-19 human immunoglobulin (1) Anti-Human Thymocyte Immunoglobulin, Rabbit (1) Anti-SARS-CoV-2 Human Convalescent Plasma (1) Anti-SARS-CoV-2 IgT seropositivity (1) Anti-SARS-CoV-2 convalescent plasma (1) Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) (1) Anti-SARS-CoV-2 immunoglobulin (1) Anti-SARS-CoV2 serological controls and serum neutralization (1) Anti-Sars-CoV-2 Convalescent Plasma (1) Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients (1) Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients (1) Antibody Test (1) Antibody test (SARS-CoV2) (1) Antibody testing (1) Antibody titration (1) Antibody-Rich Plasma from COVID-19 recovered patients (1) Anticoagulant Therapy (1) Anticoagulation Agents (Edoxaban and/or high dose LMWH) (1) Antihemophilic Factor (Recombinant) (1) Antihypertensive Agents (1) Antioxidation Therapy (1) Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 (1) Antroquinonol (1) Anxiety Reduction Training (1) Any drug used to treat Covid-19 (1) Apilimod Dimesylate Capsule (1) Apixaban (1) Apixaban 2.5 MG (1) Apixaban 5MG (1) Apo-Hydroxychloroquine (1) Appeals (1) Appendectomy (1) Apple Watch Series 5 (1) Application of tele-rehabilitation (1) Apramycin injection (1) Aprepitant injectable emulsion (1) Aprotinin (1) Arbidol Hydrochloride Granules (1) Argatroban (1) Arm exercise electrocardiographic stress test (1) Artemesia annua (1) ArtemiC (1) Artemisia Annua Leaf (1) Artemisinin / Artesunate (1) Arterial Blood Gas test (ABG) (1) Artesunate (1) Artesunate-amodiaquine (1) Ascorbic Acid and Zinc Gluconate (1) Aspirin 100mg (1) Aspirin 75mg (1) Aspirin 81 mg (1) Assembled mask (1) Assessing antibody responses, neutralizing capacity and memory B-cell function (1) Assessing impact of COVID19 (1) Assessment of Dietary Changes in Adults in the Quarantine (1) Assessment of cardiovascular diseases and cardiovascular risk factors (1) Assessment of lung mechanics and heart-lung interactions (1) Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery (1) Assessment of ventilator-associated pneumonia criteria (1) Assigned Strategies: Active Choice (1) Assigned Strategies: Enhanced Active Choice (1) Assigned Strategies: Opt-in (1) Association of diltiazem and niclosamide (1) Asthma controller therapies (incl. prednisone/prednisolone) (1) Asthma reliever therapies (1) AstroStem-V (1) Asunercept (1) Asynchronies detection (1) Asynchronous self-directed digital training (1) Atazanavir (1) Atazanavir and Dexamethasone (1) Atezolizumab (1) Atomoxetine hydrochloride (1) Atorvastatin 20 Mg Oral Tablet (1) Atorvastatin 20mg (1) Atorvastatin 40mg (1) Atovaquone/Azithromycin (1) Attention Bias Modification (ABM) (1) Attention Control Group (1) Attention Control Intervention 4 (1) Attention Training Program (1) Attention control (1) Audit and Feedback (1) Auditory Evoked Potentials (AEP) (1) Augmentin (ES)-600 (1) Auricular neuromodulation (1) Auricular percutaneous neurostimulation (1) Auscul-X (1) Auto-questionnaires (patients co infected HIV Sras-CoV-2) (1) Autologous Adipose MSC's (1) Autologous Bone Graft (1) Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) (1) Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells (1) Automated oxygen administration - FreeO2 (1) Auxora (1) Avdoralimab (1) Aviptadil 67μg (1) Aviptadil by intravenous infusion + standard of care (1) Awake Prone Positioning (1) Awake Proning (1) Awake prone positioning (1) Awake proning (1) Ayurvedic Kadha (1) Azacitidine (1) Azinc (1) Azithromycin (Azithro) (1) Azithromycin 250 MG (1) Azithromycin 250 MG Oral Capsule (1) Azithromycin 500 milligram (mg) oral Tablet (1) Azithromycin 500Mg Oral Tablet (1) Azithromycin Capsule (1) Azithromycin and hydroxychloroquine (1) Azithromycin with amoxicillin/clavulanate (1) Açaí palm berry extract - natural product (1) BACMUNE (MV130) (1) BAN2401 (1) BAT (1) BAT + Calcifediol (1) BAT2020 (1) BAX 888 (1) BAY1211163 Dose 1 (1) BAY1211163 Dose 2 (1) BAY1211163 Dose 3 (1) BAY1211163 Dose 4 (1) BAY1211163 Dose 5 (1) BAY1237592 (1) BAY2328065 LSF (1) BAY2328065 tablet (1) BBV152A - Phase I (1) BBV152A - Phase II (1) BBV152B - Phase I (1) BBV152B - Phase II (1) BBV152C - Phase I (1) BCG (1) BCG GROUP (1) BCG vaccine (Freeze-dried) (1) BDB-001 Injection (1) BGB DXP593 (1) BGB-DXP593 (1) BI 1015550 (1) BI 1358894 (1) BI 1569912 (1) BI 425809 (1) BI 706321 (1) BI 730357 (1) BIIB107 (1) BIIB133 (Dapirolizumab pegol) (1) BIKTARVY Tablets (BIK) (1) BIO 300 Oral Suspension (1) BIO101 (1) BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM (1) BIOVITALS (1) BLAfit® (1) BLD-2660 (1) BLZ945 (1) BM-Allo.MSC (1) BM-MSCs (1) BMS program (1) BMS-986253 (1) BMS-986256 (1) BMS-986259 (1) BMS-986322 (1) BMS-986322 Placebo (1) BMS-986337 (1) BMS-986337 Placebo (1) BNT162a1 (1) BNT162b3 (1) BNT162c2 (1) BRII-196 (1) BRII-198 (1) BTL-TML-COVID (1) BVA-100 (1) BVRS-GamVac (1) BVRS-GamVac-Combi (1) Bacillus Calmette-Guerin (BCG) (1) Back Side of the Moon (1) Background questionnaire (1) Bactek-R (1) Bacterial species isolated (1) Balance exercise (1) Bamlanivimab (1) Bardoxolone methyl (1) Bariatric procedures (1) Bariatric surgery (1) Baricitinib (janus kinase inhibitor) (1) Baricitinib 4 MG Oral Tablet (1) Baricitinib or Anakinra (1) Barrier box (1) Base therapy (1) Baseline and during hospitalization blood samples (1) Baseline blood sample (1) Baseline message (1) Basic Body Awareness Therapy (1) Basic Go NAPSACC (1) Beck Depression Inventory (BDI) (1) Bedside lung ultrasound (1) Behavioral Activation SSI (1) Behavioral Activation in real-life (1) Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material (1) Behavioral: OCAT (1) Behavioral: OCAT-sham (1) Behaviour Change Technique Intervention to Improve Quality of Life (1) Bemiparin sodium (1) Bemotrizinol (1) Benlysta (1) Berberine (1) Bereavement Virtual Support Group (1) Berzosertib (1) Best Available Therapy (1) Best Available Therapy (BAT) (1) Best Message + Augmented Message or Implementation Strategy (1) Best Message Alone (1) Best Standard of Care (1) Best Standard of Care + CARDIO (1) Best available care (1) Best available treatment (1) Best standard of care (1) Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy (1) Bevacizumab (1) Bimekizumab (1) BioMedomics COVID-19 IgM-IgG Rapid Test (1) Biocollection (1) Biocontainment Device For Aerosol Generating Procedures (Biobox) (1) Biological (1) Biological Sample Collection (1) Biological collection (patients co infected HIV Sras-CoV-2) (1) Biological collection with nasopharyngeal samples, saliva, blood, stool and urine (1) Biological sample and clinical data collection (1) Biological samples specific to research (1) Biological sampling (1) Biological test (1) Biological/Vaccine: Angiotensin peptide (1-7) derived plasma (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Biological: COVID-19 convalescent plasma (1) Biological: mRNA-1273: 100 mcg (1) Biological: mRNA-1273: 50 mcg (1) Biological: oral polio vaccine (1) Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT) (1) Biomarkers expression (1) Biosensor (1) Biosensors (1) Biospecimen collection (1) Bivalirudin Injection (1) Bleomycin and Vincristine (BV) (1) Blink and Masseter Inhibitory Reflex (1) Blood Collection (1) Blood D-dimer assay (1) Blood Draw (1) Blood Sample (1) Blood Test (1) Blood Transfusion (1) Blood analysis (1) Blood and derivatives. (1) Blood collection (1) Blood collection on admission and longitudinally (1) Blood collection on their first consultation and 10 to 14 days later (1) Blood donation from convalescent donor (1) Blood for anti-drug antibody (ADA) (1) Blood for pharmacokinetic samples (1) Blood for research purposes (1) Blood group determination (1) Blood plasma (1) Blood sample and data record (1) Blood sample collection (1) Blood sample for serological test (1) Blood sample for serology to measure past infection with SARS-CoV-2 (1) Blood sample for whole genome sequencing (1) Blood samples (collection of 5 mL of blood in a dry tube) (1) Blood samples collection (1) Blood test for IgG antibodies against SARS-CoV-2 (1) Blood tests sputum, nasal lavage and brushing (1) Bloodwork (1) Body Project (BP) (1) Bolus placebo (1) Bolus vitamin D3 (1) Bone Marrow Harvest (1) Bone conduction headphones (1) Bovine Lactoferrin (1) Bovine Lipid Extract Surfactant (1) Brain Health Education (BHE) (1) Brain MRI (1) Brain MRI scan (1) Brainstem Responses Assessment Sedation Score (BRASS) (1) Brazilian Green Propolis Extract (EPP-AF) (1) Breastfeeding (1) Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application (1) Breastfeeding self-efficacy (BSE) (1) Breath Biopsy (1) Breath Biopsy Analysis (1) Breath Test & Cheek Swab (1) Breath biopsy sampling using the ReCIVA Breath Sampler (1) Breath sample (1) Breath test (1) Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation (1) Brensocatib 10 mg (1) Brensocatib 25 mg (1) Brexanolone (1) Bridge therapy (1) Brief Behavioral Activation Treatment (1) Brief Behavioral Activation with Mental Imagery (1) Brief Psychiatric Rating Scale (1) Brief Skills for Safer Living (1) Brief cognitive behavioral therapy (1) Brief educational video (1) Brief informational infographic (1) Bromhexine 8 MG (1) Bromhexine Hydrochloride (1) Bromhexine Hydrochloride Tablets (1) Bromhexine Oral Tablet and/or hydroxychloroquine tablet (1) Bromhexine and Spironolactone (1) Broncho-Vaxom® (1) Bronchoalveolar Lavage (BAL) (1) Budesonide (1) Budesonide Nasal (1) Budesonide dry powder inhaler (1) Buprenorphine Sublingual Product (1) Burnout (1) Buspirone + PAP therapy (1) Butterfly (1) Butterfly iQ (1) C-reactive protein (1) C21 (1) C2Rx (1) C3+ Holter Monitor (1) CAG length <22 (1) CAG length >=22 (1) CALY-002 (1) CAM2038 (1) CAP-1002 Allogeneic Cardiosphere-Derived Cells (1) CAPABLE Transitions (1) CAStem (1) CBD Isolate (1) CBT-OSA (1) CCP (1) CCTP (1) CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc (1) CD24Fc (1) CD55 (1) CDC training (1) CDX-0159 (1) CELLECTRA™ 2000 (1) CERC-002 (1) CETA Short Session (CSS) (1) CFZ533 (1) CGB-S-100 (1) CH505TF gp120 (1) CHAMindWell (1) CHEST CT SCAN (1) CHLORPROMAZINE (CPZ) (1) CHMI (1) CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) (1) CICI - Feasibility trial study group (1) CIG Axial (1) CIG Tilted (1) CK0802 (1) CLBS119 (1) CLIA of IgG and IgM against SARS-Cov-2 (1) CME (active control) (1) CMR with T1 and T2 mapping (1) CNM-ZnAg (1) CNS magnetic resonance imaging (MRI) imaging (1) COM-COVID anonimous survey (1) COMPASS (1) CONTROL GROUP (1) CONVALESCENT PLASMA (1) COPAN swabbing and blood sample collection (1) COSH Self-help smoking cessation booklet (1) COVI-AMG (1) COVI-GUARD (1) COVI-VAC (1) COVICU (1) COVID 19 Convalescent Plasma (1) COVID 19 Diagnostic Test (1) COVID 19 Self-Questionnaire (1) COVID 19 diagnostic test by PCR (1) COVID 19 impact (1) COVID 19 serology (1) COVID WHELD (1) COVID Watch (1) COVID positive via testing (1) COVID visitation restrictions (1) COVID-19 Androgen Sensitivity Test (CoVAST) (1) COVID-19 Antibody testing (1) COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support (1) COVID-19 Breastfeeding Support (1) COVID-19 Convalescent Plasma (CCP) (1) COVID-19 Convalscent Plasma (1) COVID-19 Diagnostic and Assessment Tests (1) COVID-19 FACILITY (1) COVID-19 IgG / IgM rapid test (whole blood, serum, plasma) (1) COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) (1) COVID-19 PCR (1) COVID-19 PCR Swab (1) COVID-19 PCR and Serology (1) COVID-19 PCR and serology testing (1) COVID-19 Pandemic (1) COVID-19 Pneumonia (1) COVID-19 Specific T Cell derived exosomes (CSTC-Exo) (1) COVID-19 Swab (1) COVID-19 and Intensive Care (1) COVID-19 antibodies testing (1) COVID-19 antibody point of care test kit (1) COVID-19 barrier box (1) COVID-19 convalescent hyperimmune plasma (1) COVID-19 convalescent plasma (CCP) plus standard of care (SOC) (1) COVID-19 diagnostic PCR (1) COVID-19 diagnostic test (1) COVID-19 e-package: Psychological wellbeing for healthcare workers (1) COVID-19 experience surveys (1) COVID-19 exposure (1) COVID-19 infection (1) COVID-19 infection status (1) COVID-19 positive via testing (1) COVID-19 related health warning leaflet (1) COVID-19 standard care (1) COVID-19 survey (1) COVID-19 swap test PCR (1) COVID-19 test, polymerase chain reaction for SARS-CoV-2 (1) COVID-19 treatment (1) COVID-19 treatments (1) COVID-19+ observational (1) COVID-VIRO® test (1) COVID-surgRES questionaire (1) COVID19 (1) COVID19 convalescent plasma infusion (1) COVID19 vaccine (1) COVIDSeq Test (1) COVSurf Drug Delivery System (1) CPAP (1) CPAP treatment (1) CPI-006 (1) CRESTOR® (1) CRI management (1) CSL324 (1) CT of the chest (1) CT score (1) CT-P59/Placebo (1) CT-V (1) CT-imaging (1) CT-scan (1) CT-scan with minimal invasive autopsy (1) CTUS examination (1) CUROSURF® (poractant alfa) (1) CVL-865 High dose (1) CVL-865 low dose (1) CVnCoV (Dose level confirmed in Part 1) (1) CVnCoV 6 μg (1) CVnCoV 8 μg (1) CVnCoV 8 μg (4 μg double dose) (1) CVnCoV Vaccine (1) CYNK-001 (1) CYP 450 Substrates (1) CYP-001 (1) Cabotegravir 200 mg/mL (1) Cabotegravir 400 mg/mL (1) Cabotegravir Injectable Suspension (CAB LA) (1) Cabotegravir extended release suspension for injection (long-acting) (1) Cabotegravir sodium (Oral Lead In) (1) Caffeine 200 mg (1) Calcium Channel Blockers (1) Calm Meditation App (1) Cambridge Validated Viral Detection Method (1) Camidanlumab Tesirine (1) Camostat (1) Canakinumab 150 MG/ML [Ilaris] (1) Canakinumab Injection 300mg (1) Canakinumab Injection 600mg (1) Candesartan (1) Canine odor detection of Volatile Organic Compounds (1) Cannabidiol, pharmaceutically produced with < 5 ppm THC (1) Cannabidivarin (1) Cannabis, Medical (1) Capillary Collection & Testing (1) Capillary and salivary sampling (1) Caption AI (1) Cardiac Magnetic resonance imaging (1) Cardiac rehabilitation (1) Cardiac surgery (1) Cardiopulmonary resuscitation (1) Cardiorespiratory Exercise (1) Caring Contacts (1) Carotid Artery Reactivity Testing (1) Carrageenan nasal and throat spray (1) Carrimycin (1) Case fatality rate (1) Cash transfer (1) Ceftaroline (1) Ceftriaxone (1) Cell therapy protocol 1 (1) Cell therapy protocol 2 (1) Cellectra 2000 Electroporation (1) Cellular response (1) Cemdisiran (1) Cenicriviroc (1) Cenicriviroc (CVC) (1) Cenobamate (1) Centricyte 1000 (1) Centrum Adult (under 50) multivitamin (1) Ceralasertib (1) Cerebral compliance and hemodynamics monitoring (1) Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies (1) Certified cloth face mask plus preventive information (1) ChAd155-RG (1) ChAdOx1 nCoV-19 (Abs 260) (1) ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost (1) ChAdOx1 nCoV-19 (qPCR) (1) ChAdOx1 nCoV-19 0.5mL boost (1) ChAdOx1 nCoV-19 0.5mL prime plus boost (1) ChAdOx1 nCoV-19 full boost (1) ChAdOx1 nCoV-19 half boost (1) ChAdOx1 nCoV-19 single dose (1) ChAdOx1 nCoV-19 two dose (1) ChAdOx1-HPV (1) ChAdox1 n-CoV-19 (Abs 260) vaccine low dose (1) Change in knowledge, motivation, skills, resources (1) Change in preference to surgery under COVID-19 pandemic. (1) Chat-based instant messaging support (1) Chat-based support (1) Chest MRI (1) Chest computed tomography (CT) (1) Chest physiotherapy using a non-invasive oscillating device (1) Chinese Herbal Medicine (1) Chinese medicine treatment (1) Chiropractic care (more than one visit) (1) Chiropractic care (one visit) (1) Chlorhexidine Gluconate (1) Chloroquine Diphosphate (1) Chloroquine Phosphate Tablets (1) Chloroquine analog (GNS651) (1) Chloroquine diphosphate (1) Chlorpromazine (1) Choice of Assignment: Active Choice (1) Choice of Assignment: Enhanced Active Choice (1) Choice of Assignment: Opt-in (1) Choices and judgements (1) Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument (1) ChulaCov19 mRNA vaccine (1) Ciclesonide (1) Ciclesonide Inhalation Aerosol (1) Ciclesonide Metered Dose Inhaler [Alvesco] (1) Cimetidine (1) Cisplatin (1) Clarithromycin (1) Clazakizumab 12.5 mg (1) Clazakizumab 25 mg (1) Clevudine (1) Clinical diagnosis of COVID-19 by a health care professional (1) Clinical examination (1) Clinical interview (1) Clinical, functional and radiological lung involvement evolution (1) Clinical, laboratory and imaging characteristics of pneumonia (1) Clinolipid (1) CloSYS mouthwash (1) Clofazimine (1) Clopidogrel 75mg (1) Closed-loop control of oxygen supplementation by O2matic (1) Cloth Face Mask (1) Clungene rapid test cassette (1) Co-created intervention (1) Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) (1) Co-mestring (co-coping) (1) CoYoT1 Care (1) Coala Heart Monitor (1) Cod liver oil (1) Cognitive Behavioural Group Therapy for Perinatal Anxiety (1) Cognitive Behavioural Therapy for Insomnia (1) Cognitive Behavioural Therapy with Mindfulness classes (1) Cognitive Stimulation (1) Cognitive Training (1) Cognitive and behavioral intervention. (1) Cognitive behavioral therapy (CBT) (1) Cognitive testing (1) Cohort (1) Colchicine 0.5 MG (1) Colchicine 1 MG Oral Tablet (1) Colchicine Pill (1) Colchicine plus symptomatic treatment (paracetamol) (1) ColdZyme® mouth spray (1) Coldamaris lozenges (1) Colgate Peroxyl mouthwash (1) Colgate Total mouthwash (1) Colgate periogard mouthwash (1) Collagen-Polyvinylpyrrolidone (1) Collection of Biological Samples (1) Collection of blood samples in order to create a biocollection (1) Collection of breath sample (1) Collection of odour samples (1) Collection of samples (1) Collection of tears and saliva. (1) Colorectal resection (1) Colorectal resections (1) Combination (1) Combination of Lopinavir /Ritonavir and Interferon beta-1b (1) Combination of oral polio vaccine and NA-831 (1) Combined ART/hydroxychloroquine (1) Combined use of a respiratory broad panel multiplex PCR and procalcitonin (1) Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT) (1) Common Elements Toolbox (1) Common Elements Toolbox- Adult version (COMET-A) (1) Communication (1) Communication type (1) Community Referral as appropriate (1) Community based combination HIV prevention package (1) Community identity recruitment (1) Community interest message (1) Community-driven messages to promote COVID-19 testing (1) Comparable Placebo (1) Comparable Placebo of Oral Polio Vaccine and Placebo of drug (1) Comparable Placebo of drug (1) Comparator (1) Comparator full face mask 1 (1) Comparator full face mask 2 (1) Comparator full face mask 3 (1) Compassion focused intervention (1) Complement dosage (1) Complete thrombophilic profile testing by multiplex PCR (1) Completion of post telemedicine encounter survey (1) Completion of pre-pandemic survey (1) Completion of survey after peak of pandemic (1) Complex diagnostic panel (1) Comprehensive treatment (1) Computed Tomography (CT) (1) Computer Based Response Training Weight Loss Intervention (1) Computer task questionnaires (1) Computerized Talking Touchscreen (1) Conestat alfa (1) Conexiones (1) Confinement and Communication During the COVID-19 Pandemic (1) Conjunctival swab and nasopharyngeal swab (1) Connected devices measurements (1) Connor-Davidson Resilience Scale 10 items (CD-RISC 10) (1) Contain COVID Anxiety SSI (1) Continuation of ACEi/ARB (1) Continuation of ARB/ACEI (1) Continuation of anti-TNF treatment (1) Continuous Positive Airway Pressure (1) Continuous renal replacement therapy (1) Continuous vital sign monitoring - Isansys Patient Status Engine (1) Control (albumin 5%) (1) Control (standard clinical practice) (1) Control Blend (1) Control Group (pharmacotherapy and/or psychotherapy, n=10) (1) Control Intervention (1) Control Period (1) Control arm (1) Control for aerosol generating procedures (1) Control message (1) Control patients (1) Control swab (1) Control-EDI (1) ConvP (1) Convalescent Immune Plasma (1) Convalescent Plasma 1 Unit (1) Convalescent Plasma 2 Units (1) Convalescent Plasma as Therapy for Covid-19 patients (1) Convalescent Plasma from COVID-19 donors (1) Convalescent Plasma of patients with COVID-19 (1) Convalescent SARS COVID-19 plasma (1) Convalescent Serum (1) Convalescent anti-SARS-CoV-2 MBT Plasma (1) Convalescent anti-SARS-CoV-2 plasma (1) Convalescent plasma (CP) (1) Convalescent plasma transfusion (1) Convalesscent Plasma (1) Conventional N95 respirator (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules (1) Conventional oxygen therapy (1) Conventional physical therapy (1) Conventional therapy first (1) Cooking Training (1) Coping strategies video (1) Cord Tissue Mesenchymal Stromal Cells (1) Cordio App (1) Core Warming (1) Corn oil (placebo) (1) CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test (1) CoronaVac (1) Coronary artery calcium score and cardiac computed tomographic angiography (1) Coronavirus Disease 2019 (1) Corticosteroid injection (1) Corticosteroids and Derivatives (1) Cosentyx (1) Cospherunate/Azythromycine (1) Cospherunate/Phytomedicine/Azythromycien (1) Cost-Benefit Frame (1) Counseling Services Alone (1) Counter Attitudinal Therapy (1) Couples' Intervention (1) CovX (1) Covax-19™ (1) Covid ICU containment measures (1) Covid-19 + patients (1) Covid-19 Antibody testing (IgG and IgM) (1) Covid-19 Rapid Test Kit (RAPG-COV-019) (1) Covid-19 Standard of Care (1) Covid-19 presto test (1) Covid-19 swab PCR test (1) Covid19 (1) Covidfree@home (1) Covigenix VAX-001 (1) Covigenix VAX-001 placebo (1) Crest Pro-Health Multi-Protection mouthwash (1) Crisis intervention therapy (1) Crisis management coaching (1) Crizanlizumab (1) Cross Sectional study using scientifically validated psychometric Scales (1) Cross-sectional observational study (1) Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms (1) Cross-sectional study investigating the association of NPIs with mental health (1) Curently used therapy for COVID-19 non-critical patients (1) Current care per UCLA treating physicians (1) Customized questionnaire (1) Cyclosporin A (1) CytoSorb (1) CytoSorb 300 mL device (1) CytoSorb-Therapy (1) Cytochrome P450 (CYP) Substrates (1) Cytokine Adsorption (1) Cytokines dosage (1) Cytokines measurement (1) D-1553 (1) D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester (1) D-dimer,CBC.ESR,CRP, (1) DAS181 COVID-19 (1) DAS181 OL (1) DASS-21 instrument (depression and anxiety) (1) DAXI for injection Dose HIGH DOSE (1) DAXI for injection dose LOW DOSE (1) DAXI for injection dose MEDIUM DOSE (1) DB-001 (1) DFV890 (1) DIG Axial (1) DIG Tilted (1) DPPFit (1) DUR-928 (1) DWJ1248 (1) Dabigatran etexilate (1) Dabigatran etexilate + BI 1323495 (1) Daclatasvir 120 mg (1) Daclatasvir 60 mg (1) Daily Coping Toolkit (1) Daily Monitoring (1) Daily Vitamin D3 (1) Daily placebo (1) Danoprevir+Ritonavir (1) Dapagliflozin 10 MG (1) Dapagliflozin 10 mg (1) Darunavir and Cobicistat (1) Darunavir/Cobicistat (1) Darvadstrocel (1) Data Collection: Clinical Care Assessments (1) Data collection and clinical testing of subjects (1) Data collection and rhinopharyngeal swab (1) Data collection from blood draw (1) Data collection from lumbar puncture (1) Data collection from medical files (1) Data collection up to 1 year (1) Data monitoring for 48h within the first 12 hours of admission for COVID-19 (1) Data registry (1) Data research, database analysis (1) Ddrops® products, 50,000 IU, Oral (1) Decidual Stromal Cells (DSC) (1) Decitabine (1) Deep Breathing training (1) Deep Venous Disease Diagnostic (1) Defibrotide (1) Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days (1) Defibrotide Injection (1) Degarelix (1) Delayed diagnostics Anyplex TMII RV16 Detection (1) Delivery of iStride™ device gait treatment using telemedicine (1) DeltaRex-G (1) Dental pulp mesenchymal stem cells (1) Depression, Anxiety and Stress Scale (1) Descartes 30 (1) Description of groups caracteristics (1) Desferal 500 MG Injection (1) Desidustat (1) Detection of anti-COVID-19 antibody level (1) Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus. (1) Device used to record voice for screening (1) Dexamethasone (high dose) (1) Dexamethasone 2 MG/ML (1) Dexamethasone and Hydroxychloroquine (1) Dexcom G6 (1) Dexmedetomidine Injectable Product (1) Dexmethylphenidate (1) DiaNose (1) Diabetes type 2 (1) Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta (1) Diagnostic Laboratory Biomarker Analysis (1) Diagnostic Test: serology test for COVID-19 (1) Diagnostic examination for venous thromboembolism (1) Diagnostic mammography (1) Diagnostic test Covid-19 (1) Diagnostic test for SARS-Cov2 for patients and health staff (1) Diagnostic test for detection of SARS-CoV-2 (1) Dialectical Behavioral Therapy (DBT) Skills (1) Dialyzable Leukocyte Extract (1) Diet tracking and survey (1) Dietary Intervention (1) Dietary Supplement containing resistant starch (1) Dietary advice (1) Dietary advice and advice on timing (1) Dietary counselling on Food Groups according to IYC Feeding practices, WHO (1) Dietary intake, body composition, lifestyle, and CVD risk factors (1) Dietary program (1) Differences in triage (1) Difficulties lived by disabled children's parents in the period of COVID-19 pandemic (1) Diffusing capacity of carbon monoxide (1) DigiVis visual acuity app (1) Digital Health Literacy Intervention (1) Digital Health Online Platform (1) Digital cardiac Counseling (1) Digital intervention (1) Digital oximeter monitoring (1) Digoxin (1) Digoxin 0.25 mg (1) Diphenhydramine (1) Dipyridamole (1) Dipyridamole 100 Milligram(mg) (1) Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (1) Direct Antigen Tests for COVID-19 (1) Direct laryngoscope (1) Direct laryngoscopy (1) DirectCAM (1) Discontinuation of ACEi/ARB (1) Discontinuation of ARB/ACEI (1) Discontinuation of anti-TNF treatment (1) Discussion Board for Social Support +Basic Feedback (1) Discussion Board for Social Support+Personalized Feedback (1) Disease-modifying antirheumatic drugs (DMARDs) (1) Distilled water (1) Docetaxel (1) Dociparastat sodium (1) Doctella telehealth monitoring (1) Doctor Spot (1) Dolutegravir (1) Doppler Echo (1) Dornase Alfa (1) Dornase Alfa Inhalation Solution (1) Dose Finding Phase (MTD) (1) Dose of Tinzaparin or Dalteparin (1) Dose of tinzaparin or dalteparin (1) Double-Blind NT-I7 (1) Double-Blind Placebo (1) Double-Trunk Mask (1) Doxycyclin (1) Doxycycline Hcl (1) Drug COVID19-0001-USR (1) Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment (1) Drug: GS-5734 - 1.00 mg/kg (1) Drug: GS-5734 - 2.00 mg/kg (1) Drug: Isotretinoin plus Tamoxifen (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole (1) Drug: NA-831 (1) Drug: NA-831 - 0.10 mg/kg (1) Drug: NA-831 - 0.20 mg/kg (1) Drug: Standard treatment Standard treatment (1) Drugs and supportive care (1) Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) (1) Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) (1) DuACT (1) Duo Venous Stent System (1) Duodenal biopsy (1) Dupilumab (SAR231893/REGN668) (1) Duplex ultrasound and Computed Tomography Angiography (1) During COVID-19 Pandemic (1) Durvalumab (1) Dutasteride (1) Duty Frame (1) DynamX Bioadaptor (1) Dynamic 3D bone motion capture (1) Dysphagia Handicap Index (DHI) (1) E-cigarette ad exposure (1) ECCO2R (1) ECG from handheld device (1) ECG-Holter (1) ECMO Implantation (1) EEG (1) EG-HPCP-03a (1) EG-HPCP-03a Placebo (1) EHR-based Clinician Jumpstart (1) EIT-Group (1) ELISA (1) ELISA and Rapid test to detect antibodies against COVID-19 (1) ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB. (1) ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY (1) ELMO PROJECT AT COVID-19: STUDY IN HUMANS (1) EMDR (1) EMPOWER (1) ENT exam (1) EP (1) EPDS (Edinburgh Postnatal Depression Scale) (1) EPIC risk score display (1) EQ001 (1) EQ001 Placebo (1) ESOGER (1) ESPRIMO (1) ESPRIT™ BTK Device (1) EU-approved RoActemra (1) EUROIMMUN assay (1) EXN407 (1) EarSats Pulse Oximeter Probe (1) Early Aggressive Therapy or Traditional Therapy (1) Early rehabilitation (1) EasyCov POC (1) Echo-Doppler (1) Economic benefit message (1) Economic freedom message (1) Edinburgh Postnatal Depression Scale (EDPS) (1) Edoxaban Tablets (1) Education (1) Education sessions (1) Educational Program on Air Pollution as a Health Risk Reduction Strategy (1) Educational meetings and visual prompts (1) Educational outreach (1) Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors (1) Effortful Control Camp (1) Eicosapentaenoic acid gastro-resistant capsules (1) Ejaculated semen sample (1) Elaborative Reminiscence (ER) (1) Elagolix (1) Elective Cancer Surgery (1) Electric pad for human external pain therapy (1) Electrical Impedance Tomography (EIT) (1) Electrical Impedance tomography (1) Electrocardiogram, telemetry, echocardiogram, laboratory values (1) Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care (1) Electroencephalogram with EKG lead (1) Electronic Health Record Review (1) Electronic Survey questionnaire (1) Electronic survey (1) Electrotherapy group (1) Elisa-test for IgM and IgG to SARS-CoV-2 (1) Emapalumab (1) Embarrassment message (1) Emergency Laparotomy (1) Emergency Ventilator Splitter (1) Emergency surgery (1) Emotion Regulation Training via Telehealth (1) Emotion- and Relationship-Focused Therapeutic Interview (1) Emotional Freedom Technique (1) Emotional Support Plan (1) Emphasis of Academic Researchers Involvement (1) Emphasis of Government Involvement (1) Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet (1) Emtricitabine/tenofovir (1) Emtricitabine/tenofovir disoproxil (1) Enbrel (1) End tidal breath sample (1) Endoscopic intervention (1) Endoscopic management according to standard of care (1) Endoscopic procedure (1) Endothelial damage and angiogenic biomarkers (1) Endothermal Ablation (ETA) (1) Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19 (1) Enhanced Chronic Disease Self-management program (1) Enhanced Go NAPSACC (1) Enhanced Milieu Teaching (1) Enhanced hygiene measures (1) Enhanced linkage (1) Enhanced supervised fitness training (1) Enoxaparin 1 mg/kg (1) Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml (1) Enoxaparin Higher Dose (1) Enoxaparin Prefilled Syringe [Lovenox] (1) Enoxaparin Prophylactic Dose (1) Enoxaparin sodium (1) Enoxaparin/Lovenox Intermediate Dose (1) Enriched Survey Feedback (1) Ensifentrine Dose 1 (1) Environmental Decontamination (1) Environmental exposure and clinical features (1) Enzalutamide (1) Enzalutamide Pill (1) EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) (1) Equipment with smartwatch throughout hospital stay on the general ward (1) Ergoferon (1) Eritoran (1) Erlotinib (1) Escin (1) Esflurbiprofen hydrogel patch 165 mg (EFHP) (1) Esomeprazole 20mg (1) Esophageal temperature monitoring probe (1) Essential Oil Blend (1) Essential oils (1) Estradiol patch (1) Estrogen Therapy (1) Ethanol with Asprin (1) Etoposide (1) Etoposide (ET) (1) Evaluate HACOR score effectivity in this patients (1) Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer (1) Evaluation of clinical, instrumental and laboratory diagnostics tests (1) Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) (1) Examinations for the research: (1) Examine the impact of COVID-19 during pregnancy (1) Exercise Group (1) Exercise Intervention (1) Exercise Testing and Training (1) Exercise Training Only (1) Exercise and Cognitive Training (1) Exercise booklet (1) Exercise brochure (1) Exercise capacity (1) Exercise physiology (1) Exercise training group (1) Experiences in Close Relationship Scale questionnaire (ECR-S) (1) Experimental 1 (1) Experimental 2 (1) Experimental Group (1) Experimental drug (1) Experimental: PIVOT with MI (1) Experimental: Questionnaire without precaution information (1) Experts consensus (1) Expiratory training device (1) Exposed to the novel coronavirus disease 2019 (1) Exposure (not intervention) - SARS-CoV-2 infection (1) Exposure Therapy (1) Exposure to the Dutch measures due to the Covid-19 pandemic. (1) Exposure to the SARS-CoV-2 (1) Exposure to the SARS-CoV-2 and its consequences (1) Exposure: Covid-19 infection (1) Expression of receptors and activating proteases (1) Extended Vision IOL (1) Extended sampling and procedures (1) Extra blood sample (1) Extracorporeal Membrane Oxygenation (1) Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (1) Extracorporeal left hemicolectomy anastomosis (1) Extracorporeal membrane oxygenation (1) Extravascular Lung Water Index (1) Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol (1) EyeQue Insight (1) F-652 (1) F-FMISO PET/CT Scan (1) FAVICOVIR 200 mg Film Tablet (1) FAVIR 200 MG FT (1) FAVIRA 200 MG Film Tablet (1) FBT (1) FBT+Variety (1) FEIBA (1) FFP (1) FFP2 (1) FITSTART+ PBI (1) FLOW intervention (1) FLT3 Ligand (CDX-301) (1) FMD (1) FNC dummy tablet+Standard of Care (1) FNC+Standard of Care (1) FSD201 (1) FT516 (1) FTC/TAF (1) FTX-6058 oral capsule(s) - Two dosing periods (1) FTX-6058 oral capsule(s) / Midazolam Syrup (1) FTX-6058/placebo oral capsule(s) (1) FX06 (1) Face mask sampling (1) Face-to-face medical visits (1) Face-to-face training (1) Facial fractures reduction or osteosynthesis (1) Facial mask (1) Family Nurture Intervention (FNI) (1) FamilyChildCare (provisional name of app) (1) Farmalarm (1) Favipiravir (3200 mg + 1200 mg) (1) Favipiravir (3200 mg + 1200 mg) combined with Azithromycin (1) Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine (1) Favipiravir (3600 mg + 1600 mg) (1) Favipiravir + Currently used therapy (1) Favipiravir + Standard of Care (1) Favipiravir Combined With Tocilizumab (1) Favipiravir and Hydroxychloroquine (1) Favipiravir plus Nitazoxanide (1) Favipiravir tablets (1) Fecal Microbiota Therapy (FMT) (1) Feeling Good Digital App (1) Fenofibrate (1) Fiberoptic Bronchoscopy (FOB) (1) Fibreoptic Endoscopic Evaluation of Swallowing (FEES) (1) Fibrin generation markers assays (1) Fidaxomicin (1) File Scanning (1) File scanning (1) Filgotinib (1) FilmArray PCR on respiratory samples (1) FilmArray Pneumonia (1) Filtration Test (1) Fingerstick (1) Fingolimod 0.5 mg (1) Fit test (1) Five-days oseltamivir (1) Fixed Anchoring Strategy (1) Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) (1) Fixed-duration Hydrocortisone (1) Fixed-duration higher dose Hydrocortisone (1) Flexitouch Plus with Cellular Connectivity (FT-CC) (1) Flotetuzumab (1) Flow controlled ventilation (Evone-ventilator) (1) Flow cytometry (1) Flu shot (1) FluBlok (1) Flucelvax (1) Flurbiprofen 100 mg (1) Fluvirin (1) Fluvoxamine (1) Fluzone High Dose (1) Flywheel exercise (1) Focus Group Interviews (1) Focused/Targeted Message (1) Folfirinox (1) Folic Acid (1) Follow up calls (1) Follow-up at 14 days (1) Follow-up of patients with COVID-19 (1) Follow-up visit (1) Fondapariniux (1) Fondaparinux (1) Food Ads (1) Forced expiratory technique and induced sputum (1) Formulation without Active Drug (1) Fosfomycin disodium (1) Fostamatinib (1) Fourth Trimester Mobile Tool (1) Freestyle Libre 14 day CGM system (1) Fremanezumab-Vfrm (1) Froben 100 mg comprimidos revestidos (1) Fruquintinib (1) Full Spectrum CBD Oil (1) Functional MRI (1) Furosemide Injection Solution for subcutaneous administration (80 mg) (1) Furosemide Injection, USP (1) Fuzheng Huayu Tablet (1) GAD-7 (7-item Generalized Anxiety Disorder) (1) GAD-7 (General Anxiety Disorder) scale (1) GAD-7 General anxiety disorder scale (1) GAMUNEX-C (1) GC4419 (1) GC5131 (1) GENUS device (Active Settings) (1) GENUS device (Sham Settings) (1) GLA-SE adjuvant (1) GLPG3667 (1) GLS-1027 (1) GLS-1200 (1) GM-CSF (1) GNX102 (1) GO2 PEEP MOUTHPIECE (1) GPs reports of potential patient safety incidents, non-COVID-19 related (1) GRAd-COV2 (1) GSK2982772 (1) GSK3494245 (1) GSK3640254 200 mg (1) GSK3640254 Oral tablet (1) GSK3739937 (1) GSK3858279 (1) GSK3882347 (1) GSK3915393 Capsules (1) GSK3915393 Solution for Infusion (1) GSK3923868 (1) GX-19 (1) Gait Retraining (1) Galidesivir (1) Gam-COVID-Vac Lyo (1) Gamification (1) Ganovo+ritonavir+/-Interferon nebulization (1) Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (1) Gargle/Mouthwash (1) Gas exchange measurement (1) Gas exchanges at different PEEP (1) Gastrointestinal endoscopy (1) General Communication Message (1) General Parenting Advice (1) General Public cohort (1) General health education (1) General health through IM Apps (1) Generalized Anxiety Disorder-7 (GAD 7) (1) Generalized Anxiety Disorder-7 (GAD-7) (1) Generic Response Training Control Intervention (1) Gepotidacin (1) Gimsilumab (1) Global Longitudinal Strain (1) Glucose tablets (1) Gluten (1) Glycaemic levels (1) Glycine (1) Goal Management Training (GMT) (1) Goal-Oriented Attentional Self-Regulation (GOALS) (1) Graded exercise test (1) Graded exposure therapy (1) Group 1 (1) Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed (1) Group 2: control group with enoxaparin 40mg/d (1) Group A HCQ (1) Group A: oropharygeal spray and immunostimulant (1) Group B Control (1) Group B: Placebo oropharyngeal spray + Active principle immunostimulant (1) Group C:Active principle oropharyngeal spray + Placebo taken PO (1) Group CBT (1) Group D:Placebo oropharyngeal spray + Placebo taken PO (1) Group Exercise Classes (1) Group Lifestyle Balance (1) Group Lifestyle Balance™ (1) Group Social ABCs (1) Group1 (1) Growth Hormone (1) Growth Mindset (1) Growth Mindset SSI (1) Guanfacine hydrochloride (SPD503) (1) Guided online support program (1) Guilt message (1) HADS (1) HADS questionnaire (1) HB-adMSC (1) HCQ & AZ (1) HCQ & AZ vs HCQ+SIR (1) HCQ+AZT (1) HFB30132A (1) HFNO (1) HIIT (intervention) (1) HIT-exercise (1) HLCM051 (1) HLX70 (1) HLX71 (1) HOME-CoV rule implementation (1) HOPE intervention (1) HPV vaccine, Gardasil 9 (1) HaRTC (1) Halo Oral Spray (1) Halo Placebo (1) Hand sanitizer and hand washing (1) Haptic stimulation (1) Health Care Worker Survey (1) Health Enhancement Program (1) Health Promotion Program with cartoon education for Children with Asthma (1) Health Questionnaire (1) Health supplements (1) Health warning leaflet (1) Health-related quality of life (1) Healthy Minds Program Foundations Training (1) Healthy Weight Program (HW) (1) Healthy lifestyle advise (1) Heated Vest (1) Helmet CPAP (1) Helmet Continuous Positive Airway Pressure (CPAP) (1) Helmet non-invasive ventilation (1) Helmet non-invasive ventilation (NIV) (1) Hemanext One (1) Hemodynamics changes at different PEEP (1) Hemopurifier (1) Heparin - Prophylactic dosage (1) Heparin - Therapeutic dosage (1) Heparin Infusion (1) Heparin SC (1) Heparin sodium (1) Hesperidin and Diosmin mixture (1) Hidroxicloroquina (1) Hidroxicloroquine (1) High Dose of KBP-COVID-19 (1) High Flow Nasal Oxygen (HFNO) (1) High Intensity Interval Training group (1) High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT) (1) High Oxalate Diet (1) High PEEP with end inspiratory pause (1) High PEEP without end inspiratory pause (1) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) High dose Interferon-beta 1a (1) High dose radiation 100 cGy (1) High flow nasal cannula (1) High flow nasal cannula HFNC (1) High nitrite/NDMA meals (1) High-Concentration Essential Oil (1) High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (1) High-Titer COVID-19 Convalescent Plasma (HT-CCP) (1) High-flow nasal cannula (1) High-intensity training (1) High-titer Convalescent COVID-19 Plasma (CCP1) (1) Higher-dose (1) Home Health Agency Care (1) Home Pulse Oximetry Monitoring (1) Home Sleep Apnea Testing or In-hospital Polysomnography (1) Home exercise program (1) Home sample collection of concerning mole with physician supervision (1) Home visiting (1) Home-based exercise (1) Home-use Test and Follow-up Questionnaire (1) Honey (1) Hormones (1) Hospital admission (1) Hospital anxiety and depression scale (1) Hospital: DD-CA (1) Hospital: Usual Care (UC) (1) Hospitalized Patients for COVID-19 Infection (1) Huaier Granule (1) Human Amniotic Fluid (1) Human Biological samples (1) Human Coach first, then Virtual Assistant (1) Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs) (1) Human biological samples (1) Human milk donors (1) Human umbilical cord derived CD362 enriched MSCs (1) Human umbilical cord mesenchymal stem cells + best supportive care (1) Humanistic Care (1) Humor/Salience (1) Hydrogen Oxygen Generator with Nebulizer (1) Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03 (1) Hydroxychloroquin with Azithromycin (1) Hydroxychloroquine (placebo) (1) Hydroxychloroquine + Azithromycin (1) Hydroxychloroquine + Metabolic cofactor supplementation (1) Hydroxychloroquine + Sorbitol (1) Hydroxychloroquine + azithromycin + / - tocilizumab (1) Hydroxychloroquine + lopinavir/ritonavir (1) Hydroxychloroquine + placebo (1) Hydroxychloroquine , Sofosbuvir, daclatasvir (1) Hydroxychloroquine - Daily Dosing (1) Hydroxychloroquine - Daily dosing (1) Hydroxychloroquine Only Product in Oral Dose Form (1) Hydroxychloroquine Oral Product (1) Hydroxychloroquine Pill (1) Hydroxychloroquine Pre-Exposure Prophylaxis (1) Hydroxychloroquine SAR321068 (1) Hydroxychloroquine Sulfate (HCQ) (1) Hydroxychloroquine Sulfate + Azithromycin (1) Hydroxychloroquine Sulfate + Azythromycin (1) Hydroxychloroquine Sulfate 200 milligram (mg) Tab (1) Hydroxychloroquine Sulfate 400 mg twice a day (1) Hydroxychloroquine Sulfate 600 mg once a day (1) Hydroxychloroquine Sulfate 600 mg twice a day (1) Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets (1) Hydroxychloroquine and azithromycin treatment (1) Hydroxychloroquine and azithromycin treatment arm. (1) Hydroxychloroquine as post exposure prophylaxis (1) Hydroxychloroquine combined with Azithromycin (1) Hydroxychloroquine in combination of Azithromycin (1) Hydroxychloroquine plus Nitazoxanide (1) Hydroxychloroquine plus standard preventive measures (1) Hydroxychloroquine sulfate (1) Hydroxychloroquine sulfate &Azithromycin (1) Hydroxychloroquine, Azithromycin (1) Hydroxychloroquine, Clindamycin (1) Hydroxychloroquine, Clindamycin, Primaquine - high dose. (1) Hydroxychloroquine, Clindamycin, Primaquine - low dose. (1) Hydroxychloroquine, Doxycycline (1) Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) (1) Hydroxychloroquine/Azithromycine (1) Hydroxychloroquine/Chloroquine (1) Hydroxycloroquine and Azythromycine (1) Hyperbaric Chamber (1) Hyperbaric Oxygen (1) Hyperbaric Oxygen Therapy (1) Hyperbaric Oxygen Therapy (HBOT) (1) Hyperbaric oxygen (1) Hyperbaric oxygen therapy (1) Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device) (1) Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (1) Hyperimmune plasma (1) Hyperpolarized Xenon-129 MRI of the lungs (1) Hypertension (1) Hypocaloric, low carbohydrate diet (1) Hypocaloric, moderate low fat diet (1) Hypofractionated intensity modulated radiotherapy (1) Hypothermia Via Cooling Machine- Arctic Sun 5000 (1) IC14 (1) IC14, a monoclonal antibody against CD14 (1) ICU Recovery + Physical Therapy (1) ID NOW vs. Accula (1) IER-R (posttraumatic stress) (1) IGV-001 Cell Immunotherapy (1) IIBR-100 high-dose (prime) (1) IIBR-100 low-dose (prime-boost) (1) IIBR-100 medium dose (prime) (1) IIBR-100, low dose (prime) (1) IIEF-5 questionnaire (1) IMM-101 (1) IN01 vaccine (1) INB03 (1) INC424 / Ruxolitinib (1) INM005 (1) INO-4700 (1) INOpulse (1) IO-202 Dose Escalation (1) IO-202 Dose Expansion (1) ION-827359 (1) IP-10 in CDS protocol (1) IPSS questionnaire (1) ISIS 721744 (1) IV Deployment Of cSVF In Sterile Normal Saline IV Solution (1) IV Dexamethasone (1) IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. (1) IW-3718 (1) Ibudilast (1) Ibuprofen (1) Icatibant (1) Icosapent ethyl (IPE) (1) Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus (1) IgG (1) IgG SARS CoV 2 antibodies (1) IgG SARS CoV2 (1) IgG antibodies immunoassay (1) IgG test (1) IgIV (1) IgM and IgG diagnostic kits to SARS-CoV-2 (1) Iloprost (1) Imaging (1) Imaging by thoracic scanner (1) Imaging of the lungs (1) Imatinib (1) Imatinib Mesylate (1) Imatinib tablets (1) Imetelstat (1) Immune response study (1) Immunfluorescence (1) Immunofluorescence Imaging (1) Immunofree tablets and Reginmune capsule (1) Immunoglobulin (1) Immunoglobulin of cured patients (1) Immunoglubulins (1) Immunological profiling (1) Immunosuppressive (1) Immunosuppressive Agents (1) Impact Event Score (1) Impact of COVID-19 questionnaire (1) Impact of Event Scale-Revised (1) Implementation Facilitation (IF) (1) In-Person Default (1) In-person in clinic follow-up visit (1) In-person instruction (1) Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan (1) Inactivated SARS-CoV-2 vaccine (Vero cell) (1) Inactivated convalescent plasma (1) IncobotulinumtoxinA 100 UNT Injection [Xeomin] (1) Increasing Willingness and Uptake of COVID-19 Testing and Vaccination (1) Independent Living Program for Affordable Housing. (1) Individualised Ayurveda (1) Individualized-Chinese herbal medicine (1) Indomethacin (1) Infant Mental Health-Home Visiting (1) Infectious Disease and Cardiology Clinical Consultations (1) Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration (1) Influenza vaccination at different time points (1) Information (1) Information and referral condition (1) Information leaflet (1) Information-only intervention (1) Informational videos and social media campaigns encouraging cancer screening. (1) Informed consent (1) Infrared Energy and Dietary Supplement (1) Infusion IV of Mesenchymal Stem cells (1) Infusion of 10 mg/kg Infliximab (1) Infusion of 5 mg/kg Infliximab (1) Infusion placebo (1) Inhaled Hypertonic ibuprofen (1) Inhaled ILOPROST (1) Inhaled Supplemental Oxygen (1) Inhaled beclomethasone (1) Inhaled budesonide (1) Inhaled budesonide and formoterol (1) Inhaled nitric oxide (iNO) (1) Inhaled nitric oxide gas (1) Inhaled placebo (1) Inhaled sedation (1) Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs (1) Injection into olfactory cleft (1) Inspiratory Muscle Training (1) Inspiratory training device (1) Insulin (1) Insulin icodec (1) Insulin regimen (1) Interactive workshops LiPAT intervention group (1) Interferon alfa (1) Interferon-Alpha2B (1) Interferon-Beta (1) Interferon-ß-1a (1) Interferon-β 1a (1) Interferon-β1a (1) Interleukin 6 (IL6) Antagonist (1) Interleukin 6 (IL6) Antagonist and corticosteroids (1) Interleukin assessment in semen (1) Interleukin-1 receptor antagonist (1) Interleukin-6 Gene-174C detection (1) Intermediate dose thromboprophylaxis (1) Intermittent prone positioning instructions (1) Internet Cognitive Behavioral Therapy plus CHAMindWell (1) Internet-based Cognitive Behavioral Therapy (1) Internet-based guided self-help based on CBT principles (1) Internet-based self-help (1) Internet-based self-help after 3 weeks (1) Internet-connected computer tablet (1) Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic (1) Interpersonal Therapy (1) Intervention App (1) Intervention for COVID-19 preventive protocols (1) Intervention for TECC Model (1) Intervention group CoronaCope (1) Intervention group_rehabilitation program (1) Intervention program (1) Intervention, TBN (1) Intervention-EDI and health coaching (1) Interview by psychologists (1) Interviews only. (1) Intra-articular corticosteroid injection (1) Intracorporeal left hemicolectomy anastomosis (1) Intralipid (1) Intramuscular Vaccine (1) Intranasal heparin sodium (porcine) (1) Intraosseous access (1) Intravenous Immune Globulin (1) Intravenous Immunoglobulin (1) Intravenous Infusions of Stem Cells (1) Intravenous access (1) Intravenous drug (1) Intravenous saline injection (Placebo) (1) Intravenous sedation (1) Intubation Box (1) Invasive mechanical ventilation (1) Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours (1) Investigation of smell and taste disorders (1) Investigation of the prevalence of test positivity (1) Investigational Product - ViraCide (1) Ion Mobility Spectrometry (IMS) (1) Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops) (1) Iota-Carrageenan (1) Isoflurane Inhalant Product (1) Isoniazid, Rifampicin, Pyrazinamide and Ethambutol (1) Isoprinosine (1) Isoquercetin (IQC-950AN) (1) Isotonic saline (1) Isotonic saline 0.9% (1) Isotretinoin Only Product in Oral Dose Form (1) Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment (1) Itolizumab IV infusion (1) Ivermectin (IVM) (1) Ivermectin + Doxycycline (1) Ivermectin + Doxycycline + Placebo (1) Ivermectin + Placebo (1) Ivermectin 3mg Tab (1) Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets (1) Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU. (1) Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets (1) Ivermectin 6 MG Oral Tablet (2 tablets) (1) Ivermectin Injectable Solution (1) Ivermectin Tablets (1) Ivermectin and Doxycyline (1) Ivermectin nasal (1) Ivermectin oral (1) Ivermectin plus Nitazoxanide (1) Ivermectin wth chloroquine (1) Ixazomib Placebo (1) JNJ-53718678 (1) JNJ-53718678 125 mg (1) JNJ-53718678 2.5 mg/kg (1) JNJ-53718678 250 mg (1) JNJ-53718678 3 mg/kg (1) JNJ-53718678 4.5 mg/kg (1) JNJ-66525433 (1) JS016 (anti-SARS-CoV-2 monoclonal antibody) (1) Janus Kinase Inhibitor (ruxolitinib) (1) KELEA Excellerated Water (1) KIR phenotype evaluation (1) KOH 10 % (1) Kaletra and beta interferon (1) Kamada Anti-SARS-CoV-2 (1) Kaplan Meier analysis (1) Ketamine (1) Ketamine Hydrochloride (1) Ketamine Injectable Product (1) Ketogenic diet with phytoextracts (1) Ketotifen 1 MG (1) Kevzara sc (1) Knowledge, Attitude, Practice, Awareness, Preference (1) Kundalini Yoga and Anxiety Reduction Training (1) L-Citrulline (1) L-citrulline (1) LAMP (1) LAU-7b (1) LB1148 (1) LDAEP (1) LEAF-4L6715 (1) LIIT.CI ACT (1) LIIT.CI CFT (1) LIVE (1) LMWH (1) LNP023 (1) LRX712 (1) LSALT peptide (1) LY3127804 (1) LY3473329 (1) LYMPHOCYTE MONOCYTE RATIO (1) Lab workup (on admission and regularly during follow up). (1) Laboratory Analyses (1) Laboratory Biomarker Analysis (1) Laboratory test positive for SARS-CoV-2 virus (1) Laboratory tests (1) Lactobaciltus rhamnosus GG (1) Lactobaciltus rhamnosus GG Placebo (1) Lactoferrin (1) Lactoferrin (Apolactoferrin) (1) Lambda 180 mcg S.C (1) Lasix® (1) Late dexamethazone (1) Late-Dexamethasone (1) Lateral Position (left and right lateral decubitus) (1) Lazertinib (1) Leadership Training (1) Learning running subcuticular sutures on the Gamified Educational Network (1) Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5. (1) Lenoxin® (1) Let It Out (LIO)-C (1) Leukapheresis (1) Levamisole (1) Levamisole Pill + Budesonide+Formoterol inhaler (1) Levamisole and Isoprinosine (1) Levamisole and isoprinosine (1) Levilimab (1) Lianhua Qingwen (1) Liberase Enzyme (Roche) (1) Licensed seasonal influenza vaccine (1) Licorice extract (1) Lidocaine 2% (1) Life2000® Ventilator (1) LifeSignals Biosensor 1AX* (1) Lifelight® Data Collect Blood Pressure Group (1) Lifelight® Data Collect Oxygen Saturation Group (1) Lifestyle App (1) Lifestyle change promotion program (1) Lifestyle intervention (1) Lifestyle medicine (1) Lift (1) Limbix Spark (1) Linagliptin (1) Linagliptin 5 MG (1) Linagliptin tablet (1) Liquid Alpha1-Proteinase Inhibitor (Human) (1) Liquid Model (1) Liquid Peanut Extract (1) Listerine Mouthwash Product (1) Live Long Walk Strong rehabilitation program (1) Liver function tests ,serum ferritin and PCR for COVID-19 . (1) Liver injury (1) Local Bone Autograft (1) Local standard of care (1) Lock-down and social distancing (1) Lopinavir (1) Lopinavir / Ritonavir plus Ribavirin (1) Lopinavir / ritonavir tablets combined with Xiyanping injection (1) Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride (1) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] (1) Lopinavir 200Mg/Ritonavir 50Mg FT Reference (1) Lopinavir 200Mg/Ritonavir 50Mg FT Test (1) Lopinavir 200Mg/Ritonavir 50Mg Tab (1) Lopinavir and Ritonavir Tablets (1) Lopinavir and ritonavir (1) Lopinavir-Ritonavir Drug Combination (1) Lopinavir/ Ritonavir (1) Lopinavir/ Ritonavir Oral Tablet (1) Lopinavir/ Ritonavir Placebo (1) Lopinavir/Ritonavir + hydoxychloroquine (1) Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet (1) Lopinavir/Ritonavir 400 mg/100 mg (1) Lopinavir/ritonavir treatment (1) Losmapimod oral tablet (1) Loss Frame and Fear Appeals (1) Lovenox 40 MG in 0.4 mL Prefilled Syringe (1) Low Dose (10 mg) Control (1) Low Dose Radiation Therapy (LD-RT) (1) Low Dose of KBP-COVID-19 (1) Low Molecular Weight Heparin (1) Low Oxalate Diet (1) Low PEEP - FiO2 high (1) Low PEEP - FiO2 low (1) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Low dose CT (1) Low dose Interferon-beta 1a (1) Low dose Low molecular weight heparin or Placebo (1) Low dose Radiotherapy (1) Low dose radiation 35 cGy (1) Low dose radiation therapy (1) Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis (1) Low fat "standard care" control breakfast (1) Low flow ECMO driving by CVVH machine (1) Low nitrite/NDMA meals (1) Low or upper respiratory tract sample (1) Low-Carb High-Fat breakfast (1) Low-Carbohydrate Diet (1) Low-Concentration Essential Oil (1) Low-Intensity Psychosocial Interventions through Telemental health (1) Low-dose Chest CT (1) Low-dose radiotherapy (1) Lower-dose prophylactic anticoagulation (1) Lucinactant (1) Lumbar Puncture (1) Lung CT (1) Lung CT scan analysis in COVID-19 patients (1) Lung Cancer Screening Decision Tool (1) Lung Function Test (1) Lung Function tests (1) Lung Low Dose Radiation (1) Lung Ultrasound (1) Lung impedance technique (1) Lung ultrasound use in patients hospitalized with COVID (1) LungFit™ (1) M201-A Injection (1) MAGEC Spine Rod (1) MANAGEMENT OF COVID-19 (1) MAS825 (1) MBCT/MBSR (1) MCC IMS (1) MCN (Methylene blue, vitamin C, N-acetyl cysteine) (1) MEDI7219 (1) MELT-100 (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg (1) MFS (1) MGA012 (1) MGC018 (1) MK-5475 (1) MLS Laser (1) MMR vaccine (1) MPT0B640 (1) MR or M-M-R II ® vaccine (1) MR-Pro-ADM (1) MRI (1) MRI (heart, brain, lungs, kidney) (1) MRI scans (1) MRx-4DP0004 (1) MSB11456 (1) MSC Treatment (1) MSCT (1) MSCs (1) MSCs-derived exosomes (1) MSTT1041A (1) MSTT1041A-matched Placebo (1) MULTI-LINK 8 LL stent (1) MULTI-LINK 8 SV stent (1) MULTI-LINK 8 stent (1) MVA-BN-Filo (1) MVA-HPV (1) MVA-MERS-S_DF1 - High Dose (1) MVA-MERS-S_DF1 - Low Dose (1) MVA-SARS-2-S vaccinations (days 0 & 28) (1) MVC-COV1901 (1) MW33 injection (1) MW33 injection placebo (1) Machine Learning/AI Algorithm (1) Machine learning model (1) Macrolide administered for 3-5 days (1) Macrolide administered for up to 14 days (1) Magnetic Resonance Imaging (1) Magnetic Resonance Imaging (MRI) (1) Magnetic Resonance Spectroscopy (MRS). (1) Maintenance or reduction of immunosuppression (1) MakAir (1) Male Sexual Health Questionnaire (MSHQ) (1) Maltodextrin (1) Mannitol (1) Manremyc (1) Maraviroc (1) Maraviroc + Currently used therapy (1) Maraviroc 300 mg (1) Maraviroc+Favipiravir+CT (1) Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) (1) Masimo, LidCO (1) Masked Saline Placebo (1) Maslach Burnout Inventory (MBI) (1) Massive parallel sequencing of host genome (1) Matched Placebo Hydroxychloroquine (1) Matched placebo (1) Matching Placebo (1) Maternal stress (1) Maximal effort test (1) McGrath videolaryngoscope (1) Measles-Mumps-Rubella Vaccine (1) Mechanical Trombectomy (1) Mechanical ventilation with the automated BVM compressor (1) Med-South Weight Loss Intervention (1) Media Intervention (1) Medical Mask (1) Medical Ozone procedure (1) Medical Record Review - Inpatient Treatment (1) Medical records-based recommendation (1) Medical/surgical mask (1) Medically Tailored Meals (1) Medication Review (1) Meditation Therapy (1) Meditation and Anxiety Reduction Training (1) Meditation app usage (1) Mediterranean diet, no caloric restriction (1) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Medtronic Interstim II Model 3058 Neurostimulator (1) Mefloquine (1) Mefloquine + azithromycin + / - tocilizumab (1) Melatonin 2mg (1) Melatonin intravenous (1) Melphalan (1) MenACWY (1) MenACWY boost (1) MenACWY single dose (1) MenACWY two dose (1) MenACWY vaccine (1) MenCare+/Bandebereho fathers'/couples' group education (1) Mental Health questionnaire (1) Mental imagery (1) Mepolizumab 100 MG [Nucala] (1) Merimepodib (1) Mesenchymal Stem Cell (1) Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords (1) Mesenchymal Stromal Cells infusion (1) Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 (1) Mesenchymal cells (1) Mesenchymal stem cell (1) Mesenchymal stem cell therapy (1) Mesenchymal stem cells (1) Mesenchymal stromal cell-based therapy (1) Message directing subjects to information on COVID-19 vaccine safety and efficacy (1) Messaging (1) MetaNeb® System (1) Metacognitive therapy and work-focused interventions (1) MetfoLiquid GeriaSan® (1) Metformin XR (1) Methotrexate-LDE phase 1 (1) Methotrexate-LDE phase 2 (1) MethylPREDNISolone 80 Mg/mL Injectable Suspension (1) Methylene Blue 5 MG/ML (1) Methylene-Blue Photodisinfection (1) Methylprednisolone Injectable Product (1) Methylprednisolone Injection (1) Metoprolol 100 mg (1) Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) (1) Microcrystalline Cellulose, NF (1) Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension (1) Microscopy of defined brain regions on autopsy specimens (1) Midazolam 5 mg (2.5 mL) (1) Midazolam injection (1) Middle-dose (1) Milk of magnesia (1) MindRhythm Harmony (1) Mindful Self-Compassion (1) Mindfullness based cognitive program (1) Mindfulness + Compassion Intervention (MC) (1) Mindfulness Alone (MO) Intervention (1) Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell (1) Mindfulness Meditation (1) Mindfulness Rounds (1) Mindfulness Training (1) Mindfulness based intervention (1) Mindfulness exercises (1) Mindfulness intervention (1) Mindfulness program (1) Mindfulness session(s) (1) Mindfulness training (1) Mindfulness training (MT) Connect (1) Mindfulness-Based Cognitive Therapy (1) Mindfulness-based "STOP touching your face" practice (1) Minimal Attention Control Intervention (1) MinnRAP Peer Support Program (1) Minocycline (1) Mobile Enhanced Prevention Support (1) Mobile Mental Health App - 1 (1) Mobile Mental Health App - 10 (1) Mobile Mental Health App - 2 (1) Mobile Mental Health App - 3 (1) Mobile Mental Health App - 4 (1) Mobile Mental Health App - 5 (1) Mobile Mental Health App - 6 (1) Mobile Mental Health App - 7 (1) Mobile Mental Health App - 8 (1) Mobile Mental Health App - 9 (1) Model Building (1) Model validation (1) Moderate Intensity Aerobic Exercises (1) Moderate-intensity continuous training (1) Modified Bai He Gu Jin Tang (1) Modified Rankin score (1) Molgramostim nebuliser solution (1) Mometasone furoate (1) Monalizumab (1) Monitoring Visit - Baseline (1) Monitoring Visit - Week 4 (1) Monitoring Visit - Week 8 (1) Monitoring for aggravation (1) Monitoring physiological data with the Hexoskin smart shirt (1) Monodose RS01 (1) Montelukast 10 mg (1) Montelukast 10mg (1) Montelukast Oral Granules (1) Montmorrillonite (1) Morning Bright Light Therapy (1) Mother Provides MOM (1) Motivational social support from nurse (1) Motivational social support from nurse with additional support from significant other (1) Moxibustion plus Cupping (1) Moxifloxacin or Levofloxacin (1) Mucodentol (1) Multi Modal Balance Training (1) Multi-tasking Training (1) MultiStem (1) Multicapillary column coupled ion mobility spectrometry (1) Multifrequency Bioimpedance Spectroscopy (1) Multimodal intervention strategy (1) Multiple Doses of Anti-SARS-CoV-2 convalescent plasma (1) Multivitamin (1) Mupirocin (1) Muscle Relaxation Therapy (1) Muscle ultrasound (1) MuscleSound Ultrasound (1) Museum virtual guided tours (1) Music Therapy (1) MySafeRx Inspire Flex (1) MySafeRx Inspire Plus (1) N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I (1) N-803 (1) N-95 Respirator (1) N-acetyl cysteine (1) N95 Respirator (1) N95 respirator (1) NA (no intervention) (1) NA-831 (1) NA-831 and Atazanavir (1) NA-831and Dexamethasone (1) NAD+ (1) NBT-NM108 (1) NETosis markers (1) NG Biotech (1) NG test (1) NGM621 (1) NHANES smell and taste tests (1) NICU Acquires MOM (1) NIO® (Intraosseous access) (1) NIVOLUMAB (1) NK Cells (1) NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (1) NK-1R antagonist (1) NO gas (1) NO intervention planned due to the observational study design - only a diagnostic testing (1) NO intervention planned due to the observational study design only a diagnostic testing (1) NO-Immunosuppressive (1) NOX66 (1) NP-120 (Ifenprodil) (1) NT-I7 (1) NaCl (1) NaCl 0.9% (1) NaCl Solution (1) Nafamostat Mesylate (1) Naltrexone 380 MG (1) Narrative Exposure Therapy (1) Narrative Writing (1) Nasal Brushing (1) Nasal Dexamethasone (1) Nasal Irrigation (1) Nasal Spray (1) Nasal Swab (1) Nasal lavage (1) Naso pharyngeal swab (1) NasoVAX (1) Nasopharyngeal (NP) swab (1) Nasopharyngeal Swab (1) Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR (1) Nasopharyngeal swab and main laboratory (1) Nasopharyngeal, oropharyngeal, or saliva swab (1) Natural Honey (1) Nebulised heparin (1) Nebulised unfractionated heparin (UFH) (1) Nebulized Furosemide (1) Nebulized Platelet Lysate (1) Nebulized Saline (1) Nebulized Sterile Saline (1) Nebulized administration of RLF-100 or Placebo (1) Negative COVID Test Result - Hypothetical Scenario (1) Negative Ion Generator (1) Nemolizumab (1) NestaCell® (1) Neural network diagnosis algorithm (1) Neurocognitive assessment (1) Neuromuscular Electrical Stimulation (1) Neuromuscular evaluation (1) Neutral Aspheric Monofocal IOL (1) Neutral writing control (1) Neutralizing antibodies (1) New QIAstat-Dx fully automatic multiple PCR detection platform (1) New screening strategy (1) Newsfeed function (1) Next generation Sequencing (NGS) analysis (1) Niclosamide suspension (1) Nicotinamide riboside (1) Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour (1) Nicotine patch (1) Nigella sativa (1) Nil intervention (1) Nintedanib (1) Nintedanib 150 MG (1) Nintedanib 150 MG [Ofev] (1) Nitazoxanide 500 MG (1) Nitazoxanide 500Mg Oral Tablet (1) Nitazoxanide Tablets (1) Nitazoxanide and atazanavir/ritonavir (1) Nitazoxanide with ivermectin (1) Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation (1) Nitric Oxide delivered via LungFit™ system (1) Nitric Oxide lozenges, 30 mg (1) Nitric Oxide-Continuous and Sessions (1) Nitric Oxide-Releasing Drug (1) Nitric Oxide-Sessions (1) Nivolumab Injection (1) No Intervention - Observational Study (1) No Messaging (1) No Personal protective equipment (PPE) (1) No Racial Inequality Highlighting (1) No Treatment (1) No intervention (survey study for medical doctors). (1) No intervention - exposure is to COVID-19 (1) No intervention - quality of life measure (1) No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups (1) No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests (1) No intervention on patients (1) No intervention, observational (1) No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.. (1) No interventions (1) No interventions planned (1) No interverntion (1) No research related technology based social interactions (1) No special intervention (1) Non Extracorporeal Membrane Oxygenation (1) Non Intervention (1) Non applicable (1) Non interventional study (1) Non invasive visual acuity testing (1) Non-ACEI/ARB (1) Non-Anchoring Strategy Control (1) Non-Heated Vest (1) Non-Interventional (1) Non-Mindfulness intervention (1) Non-contact ECG (1) Non-contact MCE system (1) Non-convalescent Plasma (control plasma) (1) Non-convalescent fresh frozen plasma (Standard plasma) (1) Non-enhanced CT scan of the chest (1) Non-food Ads (1) Non-hospitalization procedures (1) Non-interventional (1) Non-interventional study (1) Non-invasive brainstem stimulation (1) Non-invasive cardiac imaging (1) Non-invasive red LLLT treatment to chest of patient. (1) Non-invasive ventilatory support (1) None - NA (1) Norketotifen (1) Normal (9%) Saline (1) Normal Saline 0.9% (1) Normal Saline Infusion + standard of care (1) Normal Saline intranasal (1) Normal saline 0.9% (1) Normal saline solution (NSS), Placebo - Phase 1 (1) Normal saline solution (NSS), Placebo - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 189 - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 1 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 2 (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) (1) Not bravery message (1) Novel laser inferometry test for CORONA virus (1) Ntombi Vimbela! intervention (1) NuSepin® 0.1 mg (1) NuSepin® 0.2 mg (1) Nudge (1) Nursing care to reduce anxiety, fear and loneliness (1) Nutrition (1) Nutrition Consult and Protein Supplementation (1) Nutrition support (1) Nutritional assessment (1) Nutritional counseling (1) Nutritional education (1) Nutritional support system (NSS) (1) Nuvastatic (1) NİCaS (1) OLO-1 Medical Molecular Sieve Oxygen Generator (1) ONC201 (1) OP-101 (1) OPT101 (1) OT Guided Cognitive Interventions (1) Obesity (1) Observation of Virtual Actions (1) Observation of Virtual Actions (step 4) (1) Observation of behavior and COVID-19 infection will be conducted. (1) Observation of patients with known, suspected, or at risk for COVID-19 infection (1) Observation only (1) Observational (registry) (1) Observational Study (1) Observational cohort study on the natural history of hospitalized SARS-COV-2 patients. (1) Observational measurement of biometric data. No change to health care provided. (1) Observational only (1) Observational study only (1) Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples (1) Obvio-19 app (1) Occupational health workers (1) Octagam (1) Octagam 10% (1) Odd/Even birth year intervention groups (1) Office FU (1) Olaparib Oral Tablet [Lynparza] (1) Olfaction testing (1) Olfactometry (1) Olfactory retraining (1) Omega 3/Nigella Sativa Oil (1) Omega 3/Nigella Sativa Oil/Anise seed capsule (1) Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice (1) Omega 3/Nigella Sativa Oil/Indian Costus (1) Omega 3/Nigella Sativa Oil/Quinine pills (1) Omega-3 Fatty Acid Supplement (1) Omeprazole 20mg (1) Omeprazole 40 mg (1) Omnibiotic AAD (1) On-Line Survey (1) On-line exercise and education (1) On-site exercise and education (1) OnabotulinumtoxinA 100 UNT [Botox] (1) One COVID-19 vaccine candidate (TMV-083) administration - High dose (1) Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop (1) Online Intervention Mental Health COVID-19 (1) Online Questionnaire (1) Online Questionnaires (1) Online Survey about Dietary and Lifestyle Habits (1) Online bibliotherapy programme (1) Online cognitive behavioral therapy (CBT) (1) Online educational intervention to enhance cultural competance (1) Online educational intervention to reduce ageism (1) Online instruction (1) Online questionnaire and interviews (1) Online support Group (1) Online training (1) Only Standard Treatment (1) Ophtamesone (1) Ophthalmologic exam (1) Opt-in Recruitment Email (1) Opt-out Recruitment Email (1) Optical Coherence Tomography (OCT) (1) Optical coherence tomography angiography (1) Optimal-Massive Intervention (1) Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East (1) Optional blood completion (1) Optional questionnaire completion (1) Oral (1) Oral 25-Hydroxyvitamin D3 (1) Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions (1) Oral fluid swab (1) Oral supplement enriched in antioxidants (1) Oral-B Mouth Sore mouthwash (1) Oropharyngeal Swab (1) Orthopaedic Surgical Procedures (1) Oseltamivir 75mg (1) Osimertinib (1) Others(No intervention) (1) Otilimab (1) Outpatient MRI (1) Oxaloacetate Medical Food/Dietary Supplement (1) Oxidative Stress ELISA Kit (1) Oxycodone and Midazolam (1) Oxycodone, Paroxetine, and Quetiapine (1) Oxygen Hood (1) Oxygen Therapy (1) Oxygen gas (1) Oxygen supply (1) Oxygen-ozone therapy, probiotic supplementation and Standard of care (1) Oxytocin (1) Ozanimod (1) Ozone auto-hemotherapy (1) P2Et (Caesalpinia spinosa extract) (1) PACE-Life (1) PARTNER-MH (1) PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test) (1) PCR for COVID-19 (1) PCR, lung ultrasound (1) PD-1 blocking antibody+standard treatment (1) PDS-08 (1) PEAR-008 (1) PEEP trial (1) PEP flute (1) PET-CT of 18F-FDG (1) PET/CT Scan (1) PF-06650833 (1) PF-06882961 20 mg (1) PF-06882961 20MG (1) PF-06939999 dose escalation (1) PF-06939999 in combination with docetaxel (1) PF-06939999 monotherapy (1) PF-07104091 + palbociclib (1) PF-07104091 + palbociclib + letrozole (1) PF-07104091 monotherapy (1) PF-07304814 (1) PH-combination therapy (1) PH-monotherapy (1) PH94B (1) PHQ-9 (9-item Patient Health Questionnaire) (1) PHQ-9 (Patient Health Questionnaire) Depression Scale (1) PHQ-9 Depression Scale (1) PHR160 Spray (1) PLACEBO GROUP (1) PLN-74809 (1) POOL LAMP (1) POOL RT-PCR (1) PP-MI Intervention (1) PRO questionnaire (1) PRO-SERO-COV (1) PROStep Dashboard (clinicians) (1) PROTECTIVE VENTILATION (1) PRV-015 (1) PSC-04 (1) PSG (1) PSQI (1) PSS (Perceived Stress Scale) (1) PT-PCR test for SARS-CoV-2 (1) PT-Pal (1) PT-X and IMT (1) PTC299 (1) PTSD (1) PWV (1) Pacebo: Calcium citrate (1) Pacel BPC (1) Pacel FDPC (1) Pacing + mindfulness (1) Package Quantity (cigarillos) (1) Paclitaxel (PTX) (1) Pacritinib (1) Palliative care assessment (1) Pamrevlumab (1) Pandemic control measures (1) Paraclinical examination (1) Paramedic Coaching (1) Parent Education (1) Parents and Infants Engaged (1) Part 1 - TL-895 (1) Part 2 - Placebo (1) Part 2 - TL-895 (1) Partially HLA-matched SARS-CoVSTs (1) Partner-assisted intervention (1) Passed infection of SARS-CoV-2 (1) Passive Microwave Radiometry (1) Patch, Nicotine (1) Patch, Placebo (1) Pathogen-specific aAPC (1) Pathways for Parents after Incarceration (1) Patient Characteristics (1) Patient Education (1) Patient Health Questionnaire (PHQ-9) (1) Patient Health Questionnaire-9 (PHQ-9) (1) Patient Navigation Program (1) Patient Status Engine (1) Patient management suffering of coronavirus infection (1) Patient sampling (1) Patient with SAR-CoV-2 infection (1) Patient-centred advice on Telephone Consultation in TB Patients: (1) Patient-only intervention (1) Patients admitted to Intensive Care Unit with SARS-CoV2 (1) Patients received standard of care treatment during hospitalization (1) Patients with the treatment agains COVID19 (1) Pectin (1) Peer Education on Exercise for Recovery (1) Peer Resilience Champion (1) Peginterferon Lambda-1a (1) Peginterferon lambda alfa-1a subcutaneous injection (1) Pegylated Interferon-α2b (1) Pegylated interferon lambda (1) Pembrolizumab (MK-3475) (1) Pemziviptadil (PB1046) (1) Pen injector (1) Penn Microbiome Therapy - 001 (1) Penn Microbiome Therapy - 002 (1) Penn Microbiome Therapy - 003 (1) Percutaneous Coronary Revascularization for STEMI (1) Percutaneous Transluminal Angioplasty (PTA) Device (1) Performance of WHEELS-I in promoting DASH/SRD adoption (1) Performance of the test antigenic and test RT-PCR (1) Performing Virtual Actions (1) Performing of lung ultrasound (1) Performing routine care (clinical and paraclinical tests) (1) Peripheral Blood (1) Peripheral blood sampling (1) Peripheral venous ultrasound (1) Personal Exercise Intervention (1) Personal Protective Testing Booth (1) Personal behaviours (1) Personal freedom message (1) Personal identity recruitment (1) Personal protective equipment (1) Personal protective equipment (PPE) (1) Personal protective equipment from biological hazard (1) Personalized Anchoring Strategy (1) Personalized ambulatory training (1) Personalized health education (1) Phentermine 37.5 Mg (1) Philips Lumify Ultrasound System (1) Phlebotomy (1) Phone Administration of Questionnaires (1) Phone interviews (1) Phone-call screening and management by a medical student/general practitioner tandem (1) Phosphate buffered saline Placebo (1) Photobiomodulation (1) Phsyiotherapy (1) Physical Activities & Activity Booklets (1) Physical Activity (1) Physical Exam (1) Physical Exercises (1) Physical Therapy (1) Physical Therapy Exercise (1) Physical exercise (1) Physician Survey (1) Physiological saline solution (1) Physiological serum (1) Physiology (1) Physiotherapy - Manual Therapy (1) Piclidenoson (1) Pilot a rapid SARS-CoV-2 testing strategy (1) Pioglitazone (1) Pioglitazone 30 mg (1) Pioglitazone 45 mg (1) Pipeline™ Flex Embolization Device with Shield Technology™ (1) Piperacillin-tazobactam (1) Piperacillin/tazobactam (1) Pirfenidone (1) Placebo (0.9% normal saline) (1) Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) (1) Placebo (Methylcellulose) capsule (1) Placebo (PB0) (1) Placebo (PBO) (1) Placebo (Plasma-Lyte 148) (1) Placebo (carrier control) (1) Placebo (for Zonisamide) (1) Placebo (human albumin 1%) (1) Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) (1) Placebo - Phase I (1) Placebo - Starch Powder Soft gels (1) Placebo 0.10 mg + 1.00 mg/kg (1) Placebo 0.20 mg + 2.00 mg/kg (1) Placebo 0.9% NaCl solution (1) Placebo 250 cc 24 hours continuous infusion for 15 days (1) Placebo Atazanavir (1) Placebo Control (1) Placebo Daclatasvir 120 (1) Placebo Daclatasvir 60 mg (1) Placebo EC-18 (1) Placebo Glycerin SLIT (1) Placebo Group (1) Placebo Hydroxychloroquine (1) Placebo Infusion (1) Placebo LSF (1) Placebo Nitazoxanide (1) Placebo Oil (1) Placebo PBMT/sMF (1) Placebo Ribavirin (1) Placebo Saline (1) Placebo Sofosbuvir/Daclatasvir 120 (1) Placebo Sofusbuvir + Daclatasvir 60 mg (1) Placebo Starch (1) Placebo Subcutaneous Solution (1) Placebo Tablet (1) Placebo Vaccine (1) Placebo comparator: DW-NI (1) Placebo comparator: DW-NS (1) Placebo control (non-behavioral infographic) (1) Placebo for Azithromycin (1) Placebo for Hydroxychloroquine (1) Placebo for Risankizumab IV (1) Placebo for Risankizumab SC (1) Placebo for Upadacitinib (1) Placebo injection (1) Placebo intravenous (1) Placebo matching to gepotidacin (1) Placebo mouthwash (water) (1) Placebo nebuliser solution (1) Placebo of FX06 (1) Placebo of Hydroxychloroquine (1) Placebo of LPV/r Tablets (1) Placebo of NICOTINE Transdermal patch (1) Placebo of excipient(s) will be administered (1) Placebo on a 0- and 14-day schedule (1) Placebo oral (1) Placebo oral capsule; From August 2020 'no additional treatment' (1) Placebo pMDI (1) Placebo patch (1) Placebo plus standard preventive measures (1) Placebo solution (1) Placebo tablet (1) Placebo to Match RDV (1) Placebo videos (1) Placebo- 0.10 mg/kg (1) Placebo- 0.20 mg/kg (1) Placebo- 1.00 mg/kg (1) Placebo- 2.00 mg/kg (1) Placebo-LDE phase 2 (1) Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine (1) Placebo/Control (1) Placebo: Emtricitabine/tenofovir disoproxil Placebo (1) Placebo: Hydroxychloroquine (1) Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells (1) Plant Polyphenol (1) Plaquenil 200Mg Tablet (1) Plasma Donation (1) Plasma IgG levels (1) Plasma exchange (1) Plasma expansion with Ringer's Acetate (1) Plasma from COVID-19 convalescent patient (1) Plasma from a volunteer donor (1) Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19 (1) Pleth variability index (1) Plethysmography & DLCO (1) Plitidepsin 1.5 mg/day (1) Plitidepsin 2.0 mg/day (1) Plitidepsin 2.5 mg/day (1) Pneumococcal 13 - valent conjugate vaccine (1) Pneumococcal Conjugate Vaccine - formulation 1 (1) Pneumococcal Conjugate Vaccine - formulation 2 (1) Pneumococcal Conjugate Vaccine - formulation 3 (1) Pneumococcal Vaccine Polyvalent (1) Pneumococcal vaccine (1) Point of care ultrasound (1) Point-of-Care Ultrasonography (POCUS) (1) Point-of-care test for SARS-CoV-2 (1) Poly I: Poly C12U (Rintatolimod) (1) Polymorphism of the HSD3B1 (1) Polyoxidonium (1) Positive COVID Test Result - Hypothetical Scenario (1) Positive Emotion Skills Course (1) Positive Minds Strong Bodies Enhanced (1) Positive Peer Journaling (PPJ) (1) Positive feedback (1) Post COVID-19 Functional Satus Scale (1) Post Traumatic Stress Disorder questionnaire (PTSD-8) (1) Post-intensive Care unit syndrome (1) Post-mortem tissue collection (1) Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 (1) Postural Positioning (1) Povidine iodine nasal swabs (1) Povidone-Iodine (PVP-I) (1) Povidone-Iodine 0.4% NI (1) Povidone-Iodine 0.5% (1) Povidone-Iodine 0.5% NI (1) Povidone-Iodine 0.5% NS (1) Povidone-Iodine 0.6% NI (1) Povidone-Iodine 0.6% NS (1) Povidone-Iodine 2% (1) Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP (1) Povidone-iodine (1) Powered Air purifying respirator (1) PrEP (1) Prasugrel (1) Prasugrel Hydrochloride 10 MG Oral Tablet (1) Pravastatin (1) Pravastatin 40 mg (1) Pre-operative breast magnetic resonance imaging (1) Prediction Market (1) Predictive factors for clinical response in patients with COVID-19. (1) Predictors adverse evolution (1) Predictors of health care provide (1) Prednisolone (1) Prednisolone 5 mg (1) Prednisone tablet (1) Pregnant women under investigation for Coronavirus or diagnosed with COVID-19 (1) Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein (1) Premier Biotech COVID-19 IgG/IgM Rapid test Cassette (1) Presatovir placebo (1) Prescription Opioid Management App (1) Presence of specific anti-SARS-CoV-2 antibodies (1) Present Tense Talk (PTT) (1) PreserVision AREDS formulation gel tabs (1) PressureWire X (1) Prevalence of COVID-19 (1) Prevenar 7 and Prevenar 13 (1) Preventive information (1) Previfenon® (1) Primary care (1) Primary care professionals reports of potential patient safety incidents, non-COVID-19 related (1) PrimePro (1) Pro BNP , Vitamin D (1) Probiorinse (1) Probiotic and LC-PUFA (1) Probiotics (1) Problem Management Plus (1) Problem-solving and relationship improvement intervention. (1) Progesterone 100 MG (1) Prognostic score (1) Progressive Exercise Training (1) Progressive cycling exercise test to exhaustion (1) Project ECHO (1) Project Health (1) Prolastin (1) Prolectin-M; a (1-6)-alpha-D-Mannopyranose class (1) Prolonged Exposure (PE) (1) Prolonged Proned Positioning (1) Promotion of flour (1) Prone (1) Prone Positioning (PP) (1) Prone decubitus (1) Prone position ventilation (1) Prone positioning (PP) (1) Prophylactic/Intermediate Dose Enoxaparin (1) Propofol (1) Propranolol Hydrochloride (1) Proprietary extract of Nerium oleander (1) Prosocial acts (1) Prospective Chart Review (1) Prospective oberservational registry (1) Prospective observation (1) Prospective study across two time-points examining the impact of viral mitigation protocols on mental health (1) Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout (1) Protocolised mechanical ventilation strategy (1) Proton Therapy (1) Prototype BMS-986165 (1) Prototype swab (1) Provision of flour (1) Proxalutamide (1) Psilocybin (1) Psychiatric counseling (1) Psycho-Social Questionnaire (1) Psycho-education (1) Psychoeducation and Safety (1) Psychoeducational intervention (1) Psychological and Behaviour Change Support (1) Psychological and physical rehabilitation based humanistic care (1) Psychological stress and adaptation at work score (PSAS) (1) Psychological treatment (1) Psychosocial stimulation and healthy eating education (1) Public Health England Gold Standard (1) Public space exposure (1) Pulmonary Function Tests (PFT) (1) Pulmonary Physiotherapy Techniques (1) Pulmonary Rehabilitation (1) Pulmonary Vascular Permeability Index (1) Pulmonary and Motor Rehabilitation (1) Pulmonary function test (1) Pulmonary function testing (1) Pulmonary function tests (1) Pulmonary ultrasound (1) Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (1) Pulse CO-Oximetry Hemoglobin measurement transcutaneous (1) Pulse Oximeter (1) Pulse oximeter (1) Pulse oximetry (1) Pyridostigmine Bromide (1) Pyronaridine-Artesunate (1) Pyronaridine-artesunate (1) Q-NRG Metobolic Cart Device (1) Q16 testing (1) QFR (1) QMF149 (1) QazCovid-in® - COVID-19 inactivated vaccine (1) QuadraMune(TM) (1) Quadrivalent RIV with 2018-2019 NH H3 strain (1) Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant (1) Quadrivalent RIV with H3 strain 1 (1) Quadrivalent RIV with H3 strain 1 and adjuvant (1) Quadrivalent RIV with H3 strain 2 (1) Quadrivalent RIV with H3 strain 2 and adjuvant (1) Qualitative Interview (1) Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) (1) Quality Improvement (1) Quality of Life (1) Quality of life assessment (1) Quality of life promotion (1) Quantitative IgG Test (1) Quantitative analysis of SARS-CoV-2 antibodies (1) Quantitative analysis of anti-SARS-CoV-2-antibodies (1) Quantitative and qualitative assessments of mental health (1) Quantra System (1) Quercetin (1) Quercetin Phytosome (1) Quercetin Prophylaxis (1) Quercetin Treatment (1) Questionaire (1) Questionnaire and interview (1) Questionnaire by phone call (1) Questionnaire collection (1) Questionnaire for evaluation of confinement on deviant sexual fantasies (1) Questionnaire forms (1) Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index (1) Questionnaire with precaution information (1) Questionnaire, phone call (1) Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too. (1) Questionnaire-based observational study (1) Questionnaires for specific phobia (1) Questionnaires on psychological quality of life (1) Questionnaires, spirometry (1) Questionnary (1) Quetiapine (1) Quick Defense (1) Quidel Sofia SARS Antigen FIA (1) Quinquina-Stevia/Azythromycin (1) RAAS inhibitor [continued standard of care] (1) RAPA-501-Allo off-the-shelf Therapy of COVID-19 (1) RAPID-3 (1) RBA-2 (1) RBT-9 (90 mg) (1) RDV (1) RECHARGE (1) REGN10933 + REGN10987 (1) REGN10933+REGN10987 (1) REGN3048 (1) REGN3051 (1) RESP301, a Nitric Oxide generating solution (1) RIA-device (Remote Investigation and Assessment) (1) RISE (1) RO6953958 (1) RO7234292 (RG6042) (1) RPH-104 80 mg (1) RS blend (1) RSV LID/ΔM2-2/1030s (1) RSV Mobile Application (1) RSV vaccine formulation 1 (1) RSV vaccine formulation 2 (1) RSVPreF3 formulation 2 (1) RSVPreF3 formulation 3 (1) RT PCR SARS-CoV-2 (1) RT-PCR Covid-19 (1) RT-PCR SARS-Cov2 (1) RT-PCR and antibody testing (1) RT-qPCR test (1) RTLS data (1) RUC-4 Compound (1) RUTI® vaccine (1) Rabies Vaccine (1) Racial Inequality Highlighted (1) Racial/Ethnic Frame (1) Radiological Detection (1) Radspherin (1) Raman analysis of saliva, characterization of the Raman database and building of the classification model (1) Ramelteon 8mg (1) Ramipril 2.5 MG Oral Capsule (1) Random Donor Plasma (1) Randomized to Delayed Cord Clamping at birth (1) Randomized to Umbilical Cord Milking at birth (1) Ranitidine (1) Rapamycin (1) Rapid Diagnostic Test vs PCR (1) Rapid Onsite COVID-19 Detection (1) Rapid detection test (1) Rapid diagnostics using Anyplex TMII RV16 Detection (1) Rapid molecular test (1) Rarefaction (1) Rayaldee 30Mcg Extended-Release (ER) Capsule (1) Razuprotafib (1) Razuprotafib Subcutaneous Solution (1) ReWalk 6.0 (1) Reading a Book (1) Real cTBS to the vmPFC (1) Real iTBS to the dlPFC (1) Real-time chat-based support through IM Apps (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid (1) Recombinant Human Interferon α2b Spray (1) Recombinant Interferon Alfa-2b (1) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo (1) Recombinant S protein SARS vaccine (1) Recombinant human alkaline phosphatase (1) Recombinant human angiotensin-converting enzyme 2 (rhACE2) (1) Recombinant human interferon α1β (1) Recombinant human plasma gelsolin (Rhu-pGSN) (1) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (1) Recombinase aided amplification (RAA) assay (1) Reconsolidation of Traumatic Memories (RTM) (1) Reduced Dose Bevacizumab (1) Reference Treatment- BMS-986165-01 (1) Reference: Favipiravir 200 mg (Avigan) (1) Referral card (1) Regadenoson (1) Regadenoson myocardial perfusion imaging stress test (1) Registery Data Collection (1) Regular Inpatient Medical Care (1) Regular messages through Instant Messaging (IM) (1) Rehabilitation (1) Rehabilitation exercise protocol (1) Reinforcement learning message delivery (1) Relamorelin 10 μg (1) Relation between frailty and clinical outcomes in elderly patients with COVID-19. (1) Relaxation (1) Relaxation Breathing (1) Relaxation Therapy (1) Remain COVID Free SSI (1) Remdesivir (RDV) (1) Remdesivir-HU (1) Remimazolam (1) Remote Caregiver Training (1) Remote Cognitive Behavioral Therapy for Insomnia (1) Remote Intensive Group Behavioral Treatment (IGBT) (1) Remote Photoplethysmography (rPPG) vital sign acquisition (1) Remote Problem Management Plus (1) Remote consultation (1) Remote controlled exercise (1) Remote pulmonary rehabilitation (1) Removal of dead space filter (1) Renin-angiotensin system inhibitors (1) Repeat SARS-CoV-2 IgG antibodies at 45-65 days (1) Replenish protein group (1) Reporting of anosmia, ageusia and other clinical symptoms (1) Repository Corticotropin Injection (1) ResCure™ (1) Resilience Program (1) Resolute Onyx (1) Respiratory Exercise Training (1) Respiratory Mechanics (1) Respiratory Training (1) Respiratory filter in-line placed with the standard mouthpiece (1) Respiratory mechanics measurement (1) Respiratory physiotherapy (1) Respiratory rehabilitation (1) Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening (1) Response and Attention Training (1) Responsive training with no video feedback (1) Responsive training with video feedback (1) Resveratrol (1) Resveratrol Placebo (1) Retrospective case-control analysis (1) Retrospective data collection (1) Reverse transcription polymerase chain reaction (1) Reverse-transcription polymerase chain reaction (RT-PCR) (1) RhACE2 APN01 (1) Riboflavin Placebo (1) Rifaximin Novel Formulation (1) Rilematovir (1) Rilematovir X mg/kg (1) Rilpivirine Injectable Suspension (RPV LA) (1) Rilpivirine extended release suspension for injection (long-acting) (1) Ringer solution (1) Rintatolimod (1) Risankizumab IV (1) Risankizumab SC (1) Risk factors (1) Risk of MERS infection (1) Risk reduction (1) Risperidone (1) Ritonavir (1) Ritonavir+Oseltamivir (1) Ritonavir/lopinavir (1) Rivaroxaban 2.5 MG (1) Rivaroxaban 2.5 Mg Oral Tablet (1) Rivaroxaban placebo tablets (1) RoActemra iv (1) RoActemra sc (1) Robot Assisted Percutaneous Cardiovascular Intervention (1) Robotic therapy (1) Rosuvastatin (Inhibitor arm) (1) Rosuvastatin (Placebo arm) (1) Rosuvastatin + BAY1817080 (1) Rosuvastatin + BI 1323495 (1) Routine Oral Care and Analgesia (1) Routine care (no SARS-CoVSTs) (1) Routine standard of care (1) Rt PCR (1) Ruconest (1) Ruxolitinib 5 MG (1) Ruxolitinib administration (1) Ruxolitinib plus simvastatin (1) SAB-301 (1) SAMBA II (Diagnostic for the Real World) (1) SAR443122 (1) SARILUMAB (1) SARS-CoV (1) SARS-CoV 2 RNA PCR Semen (1) SARS-CoV 2 RNA PCR Urine (1) SARS-CoV-2 Ab (1) SARS-CoV-2 Antibody Analysis (1) SARS-CoV-2 IgG (1) SARS-CoV-2 IgG Antibody Testing Kit (1) SARS-CoV-2 PCR (1) SARS-CoV-2 S1/S2 IgG (1) SARS-CoV-2 Specific T Cells (1) SARS-CoV-2 and/or MIS-C Exposure (1) SARS-CoV-2 antibody based IVIG therapy (1) SARS-CoV-2 antibody immunoassays (1) SARS-CoV-2 antibody test (1) SARS-CoV-2 antibody testing (1) SARS-CoV-2 convalescent plasma treatment (1) SARS-CoV-2 non-immune Plasma (1) SARS-CoV-2 plasma (1) SARS-CoV-2 questionnaire survey (1) SARS-CoV-2 rS - Phase 1 (1) SARS-CoV-2 rS/Matrix M1-Adjuvant (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2 (1) SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France) (1) SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics (1) SARS-CoV-2 serological assessment (IgG) (1) SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen (1) SARS-CoV-2 vaccine (inactivated) (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 without adjuvant (1) SARS-CoV-2 viral composition (1) SARS-CoV-2-test (1) SARS-CoV2 Autoantibody detection (1) SARS-CoV2 Infection (1) SARS-CoV2 serum antibody testing (1) SARS-Cov-2 infection (1) SARSCoV2 Convalescent Plasma (1) SBI-101 (1) SBRT (1) SCB-2019 (1) SCB-2019 with AS03 adjuvant (1) SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant (1) SCD (1) SCH Intervention (1) SCTA01 (1) SECRET questionnaire (1) SELF-BREATHE (1) SF12, EQ-5D-5L and work status standardized quantitative assessments (1) SHG (1) SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) (1) SKILLZ-Girl Enhanced football curriculum (1) SLEDD with a L-MOD (1) SMBI digital app (1) SMS message support (1) SMS messages (1) SMS-based support (1) SNDX-6352 (1) SNG001 (1) SNO (1) SOC (1) SOC + IFX-1 (1) SOC + Intravenous Famotidine (1) SOC plus 15mg/kg EB05 IV (1) SOC plus Placebo IV (1) SOC: Temozolomide (1) SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales (1) SPIN-CHAT Program (1) SPIRIT-in person (1) SPIRIT-remote (1) SSE educational intervention (1) ST-2427 (1) STC-19 score (1) STI-5656 (1) STP + COVID-19 Convalescent Plasma (CP) (1) STP + Standard Plasma (SP) (1) Saline Control (1) Saline Nasal Irrigation (1) Saline containing 1% Human serum albumin(solution without UC-MSCs) (1) Saline nasal and throat spray (1) Saline oral/nasal rinse (1) Saline placebo (1) Saline with Baby Shampoo Nasal Irrigation (1) Saline-sodium citrate (SSC) buffer (1) Saliva (1) Saliva Assay (1) Saliva and NPS test (1) Saliva sample (1) Saliva specimen (1) Saliva test kit (1) Saliva-based testing (1) Sample (1) Sample Collection/Performance Evaluation (A) (1) Sample Collection/Performance Evaluation (B) (1) Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine) (1) Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol (1) Sampling of tissue (1) Sampling salivary (1) Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab Prefilled Syringe (1) Sarilumab SAR153191 (1) Sars-Cov-2 serology (1) Sars-Cov2 serology (1) Satisfaction evaluation (1) Savicell's ImmunoBiopsy™ (1) Saxagliptin (1) Scanning Chest X-rays and performing AI algorithms on images (1) Schirmer Test I (1) Screening breast magnetic resonance imaging (1) Screening digital breast tomosynthesis (1) Screening digital mammography (1) Screening test for covid ( RT PCR and CT Chest) (1) Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] (1) Sedentary behaviour (1) Self Study (1) Self-Compassion for Chronic Pain Virtual Group Treatment Program (1) Self-Help Therapy (1) Self-System Therapy (1) Self-acupressure (1) Self-administered questionnaires (1) Self-awareness Control (1) Self-focused acts (1) Self-guided exercises (1) Self-help booklet (1) Self-help guided by a lay provider (1) Self-interest message (1) Self-management booklet (SWitCh: Stay well during COVID-19) (1) Self-prone position recommendation (1) Self-questionnary (1) Selitrectinib (BAY2731954) (1) Semen Qualitative Analysis (1) Semi-directive interview (1) Semi-structured telephone questionnaire (1) Senicapoc (1) Sensbiosys (1) Sensitivity Intervention (1) Sensitivity and Couples' Intervention (1) SensiumVitals wearable sensor (1) Sequencing (1) Seraph®-100 Microbind® Affinity Blood Filter (1) Serelogy testing, RT PCR (1) Serial seroconversion measurements in hospital employees during the COVID-19 pandemic (1) Serologic SARS-CoV-2 screening (1) Serologic assays for antibodies to SARS-CoV-2 (1) Serologic immunoassays to SARS-CoV-2 antibodies (1) Serologic testing (1) Serological Assay or IgG for SARS-CoV-2 (1) Serological analyses to be lead on a pre-existing biobank (1) Serological screening for IgG and IgM antibodies against COVID-19 (1) Serological test for COVID-19. (1) Serological testing (1) Serological tests will be applied on patients blood sampling (1) Serology (1) Serology Test (1) Serology for Covid-19 (1) Serology test follow-up (1) Seroprevalence of SARS-CoV-2 infection in patients with HIV infection (1) Serum SARs COV 2 IGg screening in health care workers (1) Serum test (1) Serum tube collection (1) Serum zinc, vitamin d vitamin b12 levels . (1) Setanaxib (1) Severe Acute Respiratory Syndrome CoronaVirus 2 detection (1) Sevoflurane inhalant product (1) Sham Attention Training (1) Sham Device Treatment (1) Sham Stimulation (1) Sham cTBS to the vmPFC (1) Sham iTBS to the dlPFC (1) Sham intervention (1) Sham irradiation (1) Shared Decision Making (1) Shock-dependent hydrocortisone (1) Sildenafil (1) Sildenafil citrate tablets (1) Silymarin (1) Simha Kriya (1) Simple chest tomography (1) Simplified Geriatric Evaluation (1) Simulation Airway Coaching (1) Simulation Intervention (1) Simulation of Repurposed Drugs for COVID-19 (1) Simultaneous EGD and colonoscopy (1) Singing for Lung Health group attendance (1) Single Session Problem-Solving Intervention (1) Single fraction whole lung radiotherapy (1) Single high dose vitamin D (1) Sirolimus 1 MG/ML (1) Sirukumab (1) Sitagliptin (1) Six Minute Walk Test (6MWT) (1) Six-minute walk test (6MWT) (1) Six-month ARV dispensing (1) Skin biopsy (1) Sleep App (1) Sleep Education (1) Sleepio (1) Slef questionnaires fulfilment (1) Small Gift (1) Smartphone application LiPAT (1) Smartphone-based voice and self-reported symptom collection (1) Smokefree Homes (1) Snorkel-based improvised personal protective equipment (1) Social ABCs (1) Social Communication and Emotional Skill Development (SCESD) module (1) Social Distancing Advertisements (1) Social Incentive (1) Social comparison Intervention (1) Social media & news consumption (1) Socialization (1) Sodium Bicarbonate (1) Sodium Chloride 9mg/mL (1) Sodium Nitrite (1) Sodium bicarbonate (1) Sofosbuvir (1) Sofosbuvir + Daclatasvir 120 mg (1) Sofosbuvir 400 MG plus Daclatasvir 200mg (1) Sofosbuvir and Ledipasvir (1) Sofosbuvir plus Ledipasvir (1) Sofosbuvir/Daclatasvir (1) Sofosbuvir/daclatasvir (1) Software Messaging (1) Sofusa DoseConnect (1) Sofusbuvir + Daclastavir 60 mg (1) Solaraze (1) Solcera (1) Soluble Urokinase Plasminogen Activator Receptor (1) Solution-Focused Support Program (1) Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA (1) Spartan COVID-19 System (1) Spartan COVID-19 Test (1) Spartan Cube Point-of Care Covid-19 test (1) Spasticity Take Control (1) Specific anti-SARS-CoV-2 antibodies (1) Specimen Collection (1) Spectrila® (1) Spironolactone 100mg (1) Sputum analysis (1) Sputum and blood sampling (1) Sputum collection (1) Sputum sample (1) St. George's Respiratory Questionnaire (SGRQ) (1) Staff Wellbeing Centres (1) Stakeholder of TIP-OA Program (1) Stamaril (live attenuated yellow fever vaccine) (1) Standar medical treatmen (1) Standar of care (1) Standard (specific) therapy for COVID-19 (1) Standard 12-lead ECG, NT-proBNP, echocardiography (1) Standard COVID-19 therapies (1) Standard Care Therapy (1) Standard Dissemination Practice (1) Standard Donor Plasma (1) Standard Dose Bevacizumab (1) Standard Incentive (1) Standard Mask (1) Standard Of Care (SOC) (1) Standard Of Care (SOC) + Placebo (1) Standard Plasma (FFP) (1) Standard Public Health measures (1) Standard SII SBCC (1) Standard Therapy Protocol (STP) (1) Standard Treatment (1) Standard Ventilation Strategy (1) Standard administration of oxygen flow (1) Standard care delivered in the isolation hospitals. (1) Standard care therapy (1) Standard charity resources (1) Standard communication email (1) Standard diagnosis test (1) Standard interface (1) Standard medical care (1) Standard mouthpiece (1) Standard of Care (Intravenous access) (1) Standard of Care (SOC) + ANG-3777 (1) Standard of Care (SOC) and Colchicine+Rosuvastatin (1) Standard of Care (SOC): Radiation Therapy (1) Standard of Care Treatment (1) Standard of Care Triple IS (1) Standard of Care thromboprophylaxis (1) Standard of care (Paracetamol) (1) Standard of care (SOC) plus placebo (1) Standard of care for SARS-CoV-2 infection (1) Standard of care management (1) Standard of care therapies (1) Standard of care therapy (1) Standard of care. (1) Standard oxygen therapy (1) Standard protein group (1) Standard screening strategy (1) Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment (1) Standard supportive care (1) Standard therapeutic protocol (1) Standard therapy (1) Standard therapy for AUD (1) Standard therapy for AUD plus Chess-based cognitive treatment (1) Standard therapy for COVID-19 according to the stablished hospital protocols. (1) Standard therapy for TUD (1) Standard therapy of COVID-19 (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation. (1) Standard treatment according to the Clinical protocols (1) Standard treatment for COVID-19 (1) Standard-of-care (1) Standard-of-care treatment (1) Standard-titer Convalescent COVID-19 plasma (CCP2) (1) Standardised questionnaires (1) Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) (1) Standards of Care (1) Standart Care given during normal examination (1) State-trait anxiety inventory scale (1) Statins (Cardiovascular Agents) (1) Stem Cell Educator-Treated Mononuclear Cells Apheresis (1) Stem Cell Product (1) Step monitoring (1) Stereotactic Radiotherapy (1) Sterile Normal Saline for Intravenous Use (1) Sterile Water for Injection (1) Sterile normal saline (0.9%) (1) Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection (1) Stool collection (1) Stool collection or fecal swab (1) Stools (1) Streptokinase (1) Stress and emotion management (1) Stretching for People with MS: An Illustrated Manual (1) Study A (1) Study Arm (1) Study B (1) Study C (1) Study D (1) Study Group (1) Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 (1) Subacute rehabilitation (1) Sublingual Methylene blue (1) Suboxone (1) Sudarshan Kriya Yoga (SKY) (1) Sulfonatoporphyrin(TPPS) plus Sunlight exposure. (1) Sulodexide (1) Sumifilam (PTI-125), 100 mg tablet (1) Supera 7.5 OD stent (1) Supine Positioning (1) Supine position (1) Supplement Drink (1) Support treatment (1) Supported Adopted Intervention 1 (1) Supported Adopted Intervention 2 (1) Supported Adopted Intervention 3 (1) Supportive Therapy SSI (1) Supraflex Cruz 60 Micron (1) Suramin (1) Surfactant (1) Surfactant assessment (1) Surge capacity (1) Surgery (1) Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail (1) Surgical Management (1) Surgical Management + Treatment (1) Surgical Stripping (1) Surgical facial mask (1) Surgical mask (1) Surgical procedures performed under general anesthesia (1) Surveillance card (1) Survey Group (1) Survey administration (1) Survey and Questionnaire (1) Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later (1) Surveys (1) Susceptibility to infection (1) Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors (1) Sustained attention (1) Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) (1) SyB V-1901 (1) Symptom Survey (1) Symptom and Exposure Surveys (1) Symptomatic drugs (1) Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) (1) Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) (1) Symptoms entered into the CovidX application (1) Symptoms questionnare (1) Synchronous large group online workshop (1) Synthetic neutralising antibodies (1) Syringe (1) Systemic indirect endovenous ozone therapy (1) T memory cells and NK cells (1) T-Detect™ SARS-CoV-2 Assay (1) T-cell receptor (TCR) repertoire (1) T3 solution for injection (1) T89 (1) TAK-018 (1) TAK-018 Placebo (1) TAK-671 (1) TAK-671 Placebo (1) TAK-788 (1) TAK-906 Maleate (1) TAK-906 Maleate Placebo (1) TAK-981 (1) TAPE-Software (1) TAVR or SAVR (1) TBD Compound 1 (1) TBD Compound 2 (1) TBD Compound 3 (1) TCC-COVID mHealth solution (1) TCM prescriptions (1) TD-1058 (1) TD-1473 [Tablet A] (1) TD-1473 [Tablet B] (1) TD139 (1) TDCS (1) TDR (1) TEACCH School Transition to Employment and Postsecondary Education (T-STEP) (1) TEAM Wheels (1) TEM-tPA (1) TERA Intervention (1) TERN-101 (1) TGplPTH1-34 in fibrin (1) TJ003234 (1) TLRs activation measurement (1) TMS (1) TNKase (1) TOF protocol (1) TRIIM Treatment (1) TRV027 (1) TXA127 (1) TY027 (1) Table Setting Training (1) Tacrolimus (1) Tafenoquine Oral Tablet (1) Take Control (1) Taking Time (1) Taking biological samples (1) Taking blood samples for analyzing progesterone levels (1) Talabostat Mesylate plus Pembrolizumab (1) Tap water (1) Taste and olfactory function evaluation (1) Taste test (1) Team Intervention (1) Tear Collection (1) Tears swab (1) Technology based social interactions (1) Technology-assisted Index (1) Teduglutide (1) Tele-Pulmonary rehabilitation (1) Tele-Yoga Therapy (1) Tele-delivered psychological intervention (1) Tele-interventions related to diabetes management and mental well-being (1) Tele-medicine platform (1) Tele-yoga therapy (1) TeleCAM (1) Teleconsultation either by phone or by computer consultation (1) Telehealth CBT (1) Telehealth Consultation (1) Telehealth coaching sessions (1) Telehealth monitoring (1) Telehealth phone calls (1) Telemedicine FU (1) Telemedicine follow-up visit (1) Telemedicine to remote outpatient visit in bariatric patient (1) Telephone Coaching (1) Telephone follow-up (1) Telephone interview (1) Telephone survey (1) Telephonic interview during the Italian lockdown. (1) Telephonic medical visit (1) Telerehabilitation-Based (1) Telesimulation (1) Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg (1) Telmisartan 20 mg/amlodipine 2.5 mg . (1) Telmisartan 20 mg/indapamide 1.25 mg (1) Telmisartan 40Mg Oral Tablet (1) Telmisartan 40mg (1) Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. (1) Temporarily holding the RAAS inhibitor [intervention] (1) Temsirolimus (1) Ten-days oseltamivir (1) Tenecteplase (1) Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) (1) Test PCR (1) Test for SARS-CoV-2 (1) Test: Favipiravir 200 mg (LOQULAR) (1) Tested for SARS-CoV-2 (regardless of the result) (1) Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals (1) Testing for SARS-CoV-2 (1) Testing of SARS-CoV-2 antibodies (1) Testing procedure for Binding antibodies (1) Tests (1) Tetrandrine (1) Text material for psychoeducation and audio for relaxation techniques (1) Text message (1) Tezacaftor/Ivacaftor + Ivacaftor (1) Thalidomide (1) The CRAFT program (adapted due to COVID-19) (1) The DryShield (1) The MBSR program (adapted due to COVID-19) (1) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: (1) The PREPARE program (1) The Vie Scope laryngoscope (1) The control group will not receive hydroxychloroquine (1) The demographic, clinical, laboratory, and instrumental data (1) The high-volume evacuator (1) The saliva ejector (1) The standard Macintosh laryngoscope (1) The standard of care (1) The study does not required (1) The usual treatment (1) Therapeutic Anticoagulation (1) Therapeutic Exercise and Education (1) Therapeutic Plasma Exchange (TPE) (1) Therapeutic Plasma exchange (1) Therapeutic plasma exchange (1) Therapeutic plasma exchange (TPE) (1) Therapist Guided E-Therapy (1) Therapist-guided one-session online exposure therapy according to (Öst, 1989) (1) Therapy Intervention (1) There is no intervention (1) There is no intervention in this study (1) Thermography (1) Thiazide or Thiazide-like diuretics (1) This is an online survey with no intervention. (1) Thoracic CT Scan (1) Thorax CT (1) Thoraxic computed tomography (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 (1) Three doses of placebo at the schedule of day 0, 14, 28(high-dose group) (1) Threshold IMT device (1) Throat swab and/or nasopharyngeal swab (1) Throat swab sample for measuring current infection with SARS-CoV-2 (1) Thrombin Generation Assay (TGA) (1) Thrombin generation test assay (1) Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) (1) Thromboprophylaxis (1) Thymosin+standard treatment (1) Ticagrelor (1) Tigerase® and best available care (1) Tinzaparin or unfractionated heparin (1) Tirofiban Injection (1) Tislelizumab (1) Tissue plasminogen activator (1) Titanium blood test (1) To assess for development of IgG antibodies against SARS-CoV2 (1) Tociliuzumab (1) Tocilizumab +/- ruxolitinib (stages 2b/3) (1) Tocilizumab 180 MG/ML (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA] (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) (1) Tocilizumab Injection [Actemra] (1) Tocilizumab Prefilled Syringe (1) Tocilizumab and Ruxolitinib (Advanced stage 3) (1) Toffee Full Face Mask (1) Tomeka® (1) Toraymyxin PMX-20R (PMX Cartridge) (1) Toremifene (1) Tracheal intubation and cardiopulmonary resuscitation (1) Tracheal suction (1) Tracheostomy (1) Tracheostomy with aerosol box in COVID-19 positive patients (1) Tracheotomy (1) Tradipitant (1) Traditional Chinese Medicine Prescription (1) Traditional Proning Arm (1) Traditional antirheumatic drugs (1) Training (1) Training and Technical Assistance (1) Training clinicians in basic critical care and the management of severe COVID-19 cases (1) Training for Awareness, Resilience, and Action (TARA) (1) Training load (1) Training of youth, community health assistants and community health workers. (1) Training session adressing information and health literacy (1) Training video on anxiety, fear and loneliness in the COVID-19 environment. (1) Training, Tech. Assistance, Quality Assurance/Improvement (1) Tramadol (1) Tranexamic acid (1) Tranexamic acid tablets (1) Trans Sodium Crocetinate (1) Transcendental meditation (1) Transcranial Electrical Stimulation (1) Transcutaneous Auricular Vagus Nerve Stimulation (1) Transfusion of COVID-19 convalescent plasma (1) Transfusion of SARS-CoV-2 Convalescent Plasma. (1) Transfusion of standard Plasma. (1) Transitional Online Peer Support Group (n=20) (1) Transparent, reusable respirator (1) Transplant patient (1) Transpulmonary pressure measurements (1) Transpulmonary thermodilution (1) Trauma Informed Psychotherapy (1) Trauma Informed Yoga (1) Trauma-informed yoga video recording (1) Treadmill electrocardiographic stress test (1) Treamid (1) Treatment (1) Treatment A (1) Treatment As Usual (1) Treatment B (1) Treatment C (1) Treatment and prophylaxis (1) Treatment as usual (1) Treatment as usual vitamin D (1) Treatment for COVID-19 (1) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : (1) Treatment with Dexmedetomidine (1) Tremelimumab (1) Triazavirin (Riamilovir) (1) Trimethoprim Sulfamethoxazole (TMP/SMX) (1) Trimodulin (1) Trivia Training (1) Trust in science message (1) Tuberculin test (1) Two COVID-19 vaccine candidate (TMV-083) administrations - High dose (1) Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose (1) Two dose MenACWY vaccine (1) Two dose MenACWY vaccine min. 4 weeks apart (1) Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly (1) Two doses of placebo at the emergency vaccination schedule (1) Two doses of placebo at the routine vaccination schedule (1) Two doses of placebo at the schedule of day 0, 28(high-dose group) (1) Two doses of placebo at the schedule of day 0, 28(middle-dose group) (1) Tympanic Temperature (1) UB-612 (1) UCMSCs (1) UCPVax + Nivolumab (1) ULTRAPROTECTIVE VENTILATION (1) UNI911 INHALATION (1) UNIKINON (Chloroquine phosphate) 200mg tablets (1) UTTR1147A (1) UTTR1147A-matched Placebo (1) UV Light Treatment (1) Ulinastatin (1) Ultimaster Tansei 80 Micron (1) Ultra Brief Online Mindfulness-based Intervention (1) Ultra-Low-dose radiotherapy (1) Ultrasonography (1) Ultrasound lung imaging as part of FAST+ evaluation (1) Ultrasound of the lower limbs (1) Umbilical Cord Lining Stem Cells (ULSC) (1) Umbilical Cord Mesenchymal Stem Cells (1) Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. (1) Umbilical cord Wharton's jelly-derived human (1) Umbilical cord derived mesenchymal stem cells (1) Umifenovir (1) Unavailable COVID Test Result - Hypothetical Scenario (1) Unfractionated Heparin IV (1) Unfractionated heparin SC (1) Unfractionated heparin nebulized (1) Unified Protocol for COVID-19 Parenting Stress (UP-COVID) (1) Uniform random message delivery (1) Universal Screening Arm (1) Unsupervised exercise (1) Unsupervised physical activities (1) Upadacitinib (1) Upadacitinib (ABT-494) (1) Urinary Incontinence (1) Urine Test (1) Urine collection (1) Urine sample (1) Use of Doctorgram Mobile Application (1) Use of Doctorgram Patient Kit (1) Use of Facetime with child and parents during induction (1) Use of Remote Pulse Oximeter (1) Use of mobile application (1) Use of social media during COVID-19 (1) Use of the pinpointIQ solution (physIQ, Inc.) (1) Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures (1) Usual Care Only (1) Usual Care plus Customized Referrals (1) Usual antibiotic treatment (1) Usual care positioning with no instructions (1) V-SARS (1) V/Q SPECT-CT (1) V/Q Vest (1) V590 (1) V591 (1) VC (1) VCPM (1) VESTA respirator (1) VIB4920 (1) VIB7734 (1) VIP4SCI (1) VIR-7831 (1) VITROS Anti-SARS-CoV-2 IgG test (1) VR for psychoeducation and relaxation (1) VRC-FLUNPF0103-00-VP VRC-FLUNPF0103-00-VP (H10ssF-6473) (1) VRC-MALMAB0100-00-AB (1) VRC-SRSDNA015-00-VP (1) VXA-CoV2-1 (1) Vaccine (1) Vaginal fluid Covid-19 PCR test (1) Valbenazine (1) Valproate (1) Valsartan (Diovan) (1) Values Clarification and Attitudes Transformation (VCAT) Workshop (1) Vancomycin (1) Vancomycin with Taper/Pulse (1) Vascular surgery (1) Vehicle (1) Vehicle + Heparin along with best supportive care (1) Vehicle Control (1) VenaSeal™ Closure System (1) Venepuncture (1) Venous Draw & Testing (1) VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (1) Ventil - a gas flow divider (1) Verapamil (1) Veru-111 (1) VibroLUNG (1) Video (1) Video Chat + Basic Feedback (1) Video Chat +Personalized Feedback (1) Video Dance classes (1) Video Default (1) Video Visit (1) Video about safety and effectiveness of adult seasonal flu vaccination (1) Video based aerobic exercise (1) Video based exercise (1) Video-Based (1) Video-Based intervention (1) Videofluoroscopic Swallowing Study (VFSS) (1) Videofluoroscopy (1) Vie Scope laryngoscopy (1) Vielight RX Plus (1) Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic (1) Viral Specific T-cells (VSTs) (1) Virtual ACT Workshop for Emotional Eating (1) Virtual Assistant first, then Human Coach (1) Virtual Care and Remote Automated Monitoring (1) Virtual Care at Home (1) Virtual Group Exercise (1) Virtual Group Intervention (1) Virtual Peer Support Platform (1) Virtual Reality Behavioral Activation (1) Virtual Reality Goggles (1) Virtual Reality Pain Neuroscience Education (1) Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) (1) Virtual reality therapy first (1) Virtual-Care Cognitive Behavioural Therapy (1) Viruxal Oral and Nasal Spray (1) Vit D (1) VitalConnect Vital Sign Patch (1) Vitamin B12 (1) Vitamin C tablets (1) Vitamin D 1000 IU (1) Vitamin D3 or Placebo (1) Vitamin E (1) Vitamins (1) Vitamins and Minerals (1) Viusid and Asbrip (1) VivaDiag™ COVID-19 lgM/IgG Rapid Test (1) ViviGen® Cellular Bone Matrix (1) Voice Symptom Scale (VoiSS) (1) Volunteer of TIP-OA Program (1) Voraxaze (1) Voriconazole Inhalation Powder (1) WALC-R (1) WEB BASED EDUCATION (1) WFI 5% glucose (1) WFI water nebulization (1) WFIT (1) WHO recommendations (waiting condition) (1) WHOQOL-BREF (1) WHOQOL-BREF survey (1) WJ-MSCs (1) WW (1) Wait list time (1) Wait-list control (1) Waiting list (1) Waiting list where participants wait for delayed treatment (1) Waitlist (1) Walk Test (1) Water Without an Elevated Level of KELEA (1) Wearable Activity Trackers, Exercise Prescription and Virtual Care (1) Wearable Medical Device (Empatica E4) (1) Wearing surgical face mask sprayed with hypertonic saline (1) Web + text smoking cessation intervention (1) Web Based Questionnaire (1) Web Based Survey (1) Web application users (1) Web-based REDCap survey (1) Web-based psychosocial peer-to-peer support (1) Web-based self-report questionnaires (1) WebEx Physical Activity Program (1) Weck-cel Swab Collection (1) Weekly Assessment (1) Weight Counseling (1) Weight Loss (1) Wellness (1) Wharton's jelly derived Mesenchymal stem cells. (1) White Sender in Acknowledgement (1) White Sender in Informational Videos (1) Whole Exome Sequencing (1) Whole Genome Analysis (1) Whole exome sequencing (1) Withings ScanWatch (1) Without haptic stimulation (1) Woebot Substance Use Disorder (1) Women receiving extra remembering by healthcare (1) Workshops control group LiPAT (1) Wrist-worn feedback physical activity monitor (1) Written Information (1) Written Summary of Rounds (1) XAV-19 (1) XC221 (1) XCEL-UMC-BETA (1) XIENCE PRIME BTK stent (1) XatJove Anoia Aplication (1) Xiyanping injection (1) Xpert Pro stent (1) YH25448 (1) Yin Hu Qing Wen Granula(low does) (1) YinHu QingWen Decoction (1) YinHu QingWen Decoction(low dose) (1) Yinhu Qingwen Granula (1) Yoga Nidra (1) Yoga group (1) Zanubrutinib (1) Zaritt Burden Interview (1) Zavegepant (BHV-3500) (1) Zilucoplan® (1) Zinc (Placebo) (1) Zinc Citrate (1) Zinc Gluconate (1) Zinc Picolinate (1) Zinc Picolinate Placebo (1) Zinc Sulfate (1) Zinc gluconate (1) Zithromax Oral Product (1) Zofin (1) Zolpidem + PAP therapy (1) Zonisamide (1) [14C]-GSK3640254 intravenous infusion (1) [14C]-GSK3640254 powder (1) [14C]-radiolabelled BI 1358894 (1) [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL) (1) [68Ga]Ga-DOTA-(RGD)2 PET/CT (1) [TIMP-2]*[IGFBP-7] (1) a specifically designed self-administered questionnaire (1) a survey (1) acetylsalicylic acid (1) actigraphy (1) acute kidney injury (1) additional blood tubes (1) aerosol box (1) aerosolized DNase (1) after-each-case room disinfection (1) agenT-797 (1) airway management during sedation or general anesthesia (1) all treatment about COVID-2019 (1) allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) (1) allogeneic mesenchymal stem cell (1) alpha one antitrypsin inhalation (1) alveolar recruitment (1) amlodipine 5 mg/indapamide 2.5 mg (1) amoxicillin/clavulanate (1) anti-CD40 antibody (CDX-1140) (1) anti-SARS-CoV-2 IgY (1) anti-SARS-CoV-2 human convalescent plasma (1) anti-SARS-CoV-2 plasma (1) antidiabetic treatment (1) antithymocyte globulin (rabbit) (1) appendectomy (1) artus Influenza A/B RT-PCR Test (1) assessment of the sequelae after hospitalization for Sars-COV-2 (1) attendance by ambulance crew (1) auscultation by using traditional stethoscope and electronic stethoscope under full PPE (1) autologous adipose-derived stem cells (1) autopsy (1) avdoralimab (1) azithromycin (1) azoximer bromide (1) bacTRL-Spike (1) behavioral lifestyle intervention (1) belatacept (1) bidirectional oxygenation mouthpiece (1) biochemical analysis (1) biological assays in particular on the lipid metabolism (1) biological samples collection (1) biological samples day of delivery (1) biological samples, questionnaires and interviews (1) biopsies of subcutaneous adipose tissue (1) blastocyst-stage embryo transfer (1) blood collection via fingerprick (1) blood sample for seroepidemiological investigation (1) blood sampling for biobank (1) blood test for SARS-COV2 serology (1) blood tests (1) bromelain (1) bronchoscopy examination (1) canakinumab (1) captopril 25mg (1) care as usual (1) care modalities (1) carotid-femoral pulse-wave velocity (1) cellulose-containing placebo capsules (1) cenicriviroc (1) chest radiography (1) chest x-ray (1) chiropractic team (1) chlorine dioxide 3000 ppm (1) chloroquine (1) cholecalciferol 200,000 IU (1) cholecalciferol 50,000 IU (1) chronic pain team (1) cleavage-stage embryo transfer (1) collection of biological samples (1) collection of mucosal lining fluid (1) collection of swabs (1) community health worker support (1) comparison of sample collection methods (1) complication (1) computerized cognitive training (CCT) (1) congenital malformation (1) conjunctival RT PCR (1) conjunctival swab (1) consultation (1) control (1) convalescent plasma application to SARS-CoV-2 infected patients (1) convalescent plasma from recovered COVID 19 donor (1) conventional management of patients (1) conventional oxygen (1) corticosteroid nasal irrigation (1) covid-19 positive pregnant women (1) ctDNA blood sampling (1) current IPAC-UHN PPE (1) daily room disinfection (1) daily syndromic surveillance (1) dapansutrile capsules (1) data record (1) decisions of limitations and stop processing (1) demographic and clinical data obtained from hospital's electronic medical record. (1) diagnostic (1) diagnostic tests for COVID-19 infection (1) dialysis (1) digoxin (1) double gloves (1) draw blood (1) e-Psychotherapy (1) e-ink screen (1) eHealth (1) eHealth +counselling contacts (1) eM2M (1) ePNa-CheXED (1) echocardiogram 2D (1) eculizumab (1) efgartigimod IV (1) efgartigimod PH20 SC (1) electrolytes (1) ensoETM device (1) ensoETM. Esophageal cooling during AF ablation (1) enzalutamide (1) enzalutamide Placebo (1) epidemiological and demographic characteristics (1) evaluation of skin microvascular flow and reactivity (1) everolimus (1) exchange blood transfusion from normal donor (1) exercise brochure (1) exposure (1) fMRI (1) faecal sample collector (1) famotidine (1) favipiravir (1) favipiravir tablets+chloroquine phosphatetablets tablets (1) favorable outcome (1) feces samples (COVI-BIOME ancillary study) (1) fingertip tests for POC assays (1) fostamatinib (1) fsfi survey (1) further processing of health data (1) gammaCore® (Vagus nerve stimulation) (1) gammaCore® Sapphire (non-invasive vagus nerve stimulator) (1) global survey (1) hAd5-S-Fusion+N-ETSD vaccine (1) high flow nasal cannula (HFNC) (1) high flow nasal cannula device (1) high-titer anti-Sars-CoV-2 plasma (1) home care monitoring (1) home spirometry (1) hormones (1) hospitalisation, necessity of ICU, mortality rate, lung involvement (1) hospitalization for premature birth (1) hospitalized children with Covid19 (1) human cord tissue mesenchymal stromal cells (1) hydrocortisone (1) hydroxychloroquine + azithromycin (1) hydroxychloroquine in combination with camostat mesylate (1) hydroxychloroquine placebo (1) hydroxychloroquine sulfate 200 MG (1) hyper immunoglobulins containing anti-Corona VS2 immunoglobulin (1) hyperbaric oxygen therapy (HBOT) (1) hyperimmune plasma (1) hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint (1) iAMP test (1) iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System (1) identify SARS-CoV-2 infection by serology (1) imPulse™ Una e-stethoscope (1) imaging, blood tests (1) immunoSEQ Dx (1) impliminting Online Distance Learning (1) in-hospital mortality rate (1) indirect calorimetry (1) inhalable hydroxychloroquine (HCQ) (1) inhaled hydroxychloroquine (1) inhaled type I interferon (1) inspiratory muscle traiing (1) insurance navigation (1) intensive care unit admission ratio (1) interleuken 6 level measurment (1) intermediate dose Enoxaparin/ unfractionated heparin (1) intermittent theta burst stimulation (iTBS) (1) intradermal injection of BCG Vaccine (1) intravenous immunoglobulin therapy (1) intubation (1) ioveraº (1) ioveraº sham (1) it is a survey (1) iv Tocillizumab (TCZ) (1) laboratory biomarkers (1) labs (1) lanadelumab (1) laparoscopic or open appendicectomy (1) lay telephone coaching (1) less-frequency hemodialysis (1) leucovorin (1) life questionnaires (1) lifestyle modification (1) liposomal lactoferrin (1) lopinavir/ritonavir (1) lopinavir/ritonavir group (1) lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate (1) low-dose (1) low-molecular-weight heparin (1) lulizumab pegol (1) lung mechanics at different PEEP (1) lung ultrasound (1) lung ultrasound (LUS) (1) mHealth Assessments (1) mMRC (Modified Medical Research Council) Dyspnea Scale (1) mRNA in urine test (1) management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia (1) mavrilimumab (1) measurement of circulating sFlt1 concentration (1) mechanical ventilation (1) mechanical ventilator settings and position (1) media multi-task (1) media package (1) melatonin (1) meplazumab for injection (1) mesenchymal stem cells (1) metenkefalin + tridecactide (1) methylprednisolone (1) methylprednisolone therapy (1) mind. body. voice (1) mindfulness, emotion didactics, interpersonal skills, experiential learning (1) miniprobe Alveoflex (1) mobile internet survey on self-test (1) modification of the planned therapeutic management (1) modified IPAC-UHN PPE (1) molecular testing for virus RNA using RT-PCR (1) mometasone furoate nasal spray (1) monthly serologic IgM/G test (1) morning Yoga-based breathing support (1) mortality (1) mouthrinse with bêta-cyclodextrin and citrox (1) mouthrinse without bêta-cyclodextrin and citrox (1) multipeptide cocktail (1) muscle ultrasound (1) mycophenolate mofetil (1) mycophenolate mofetil (MMF) (1) mycophenolic acid (1) nCapp, a cell phone-based auto-diagnosis system (1) nangibotide (1) nasal pharyngeal (NP) swab samples (1) nasopharyngeal Covid 19 RT-PCR (1) nasopharyngeal and throat swab (1) nebulised recombinant tissue-Plasminogen Activator (rt-PA) (1) nebulization (1) newborns from covid 19 positive mothers (1) no intervention-mechanistic study (1) no intervention. observational cohort study (1) no interventional study (1) non (1) non applicable (1) non e-cigarette TV commercials (1) non interventional (1) non-RAS blocking antihypertensives (1) non-contact magnetically-controlled capsule endoscopy (1) non-interventional (1) none - observational (1) none, this study is observational (1) noninvasive ventilation (1) normal saline (1) nosocomial infection/hospital acquired infection (1) not applicable (observational study) (1) nutritional intervention (1) oSOC (1) observation (1) observation of covid 19 pneumonia (1) olfactory and gustatory tests (1) olfactory device (1) online KKH Sports Singapore Program with Usual Care (1) online mindfulness group (1) online questionnaires (1) online survey (1) oral co-trimoxazole (1) oral polio vaccine + information (1) oropharyngeal swabs (1) oxygen treatment (1) oxyhydrogen (1) pathogen reduced SARS-CoV-2 convalescent plasma (1) patients COVID 19 (1) patients receiving nasal high flow (1) performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection (1) peripheral blood draw (1) phone call (1) photobiomodulation and photodynamic therapy (1) pirfenidone (1) placebo (hartmann plus albumine) (1) placebo capsules (1) placebo for clazakizumab (1) placebo for risankizumab IV (1) placebo rinse (1) placebo+rHuPH20 (1) plasma from convalescent patients with COVID-19 (1) plasma hyperimmune (1) plasma therapy using convalescent plasma with antibody against SARS-CoV-2 (1) poractant alfa (1) positive psychological intervention (1) power breathe (1) prayer (1) pre-operative screening (1) pre_dinner Yoga-based breathing support (1) pre_lunch Yoga-based breathing support (1) predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables? (1) prednisolone (1) proper diet (1) prophylactic heparin (1) prophylactic lactoferrin daily (1) psycho-education video (1) psychological and sociological interviews (1) psychological assessment (1) pulmonary anomalies 4 months after documented COVID-19 pneumonia (1) pulmonary ultrasound (1) pulse oximeter (1) qRT-PCR and serology (1) quality of life questionnaires (1) quality of live assessment (1) quesionnair (1) questionaire to husband and wife (1) questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality (1) questionnaire and optional interview (1) questionnaire filling (1) quetionnary (1) rDirectCAM (1) rapid salivary test (1) rapid serological test (1) reSET-O (1) realtime PCR (1) recombinant human interferon Alpha-1b (1) recovered covid 19 patients plasma (1) rectal swab (1) regular care (1) remdesivir (1) research specific blood sample (1) respiratory function rehabilitation training (1) retrospective metagenomics on clinical samples collected during hospitalization (1) rhDNase I (1) rhPTH(1-84) (1) risankizumab (1) risk factors (1) rosuvastatin (1) saint george respiratory questionnaire (1) saliva collection (1) saliva sample (1) samling of oropharynx and nasopharynx (1) sample of blood and saliva (1) self-administered structured questionnaire (1) self-care tools (1) semaglutide (1) semen analysis (1) serological test (1) serology test (1) sertraline (1) serum NGAL and cystatin c (1) serum chemistry analysis (1) serum inflammatory biomarkers (1) service of questionnaire (1) severe covid-19 pneumonia with ET (1) severity of lung involvement with COVID-19. (1) sham TMS (1) slow-wave disruption (1) smell household Items (1) smell the odors of the olfactory rehabilitation kit according to the classic or intensive method (1) sodium chloride 0.9% (1) sofosbuvir (1) some risk factors that might be correlated with TMD (1) specific exercise rehabilitation treatment (1) spirometry (1) spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire (1) standard chemotherapy (1) standard concomitant therapy (1) standard medical treatment (1) standard newborn and infant care (1) standard operating procedures (1) standard procedure (1) standard prophylactic dose Enoxaparin/ unfractionated heparin (1) standard protocol (1) standard treatment (1) standard western medicine treatment (1) standardized Lung Ultrasound (LUS) examination (1) stem cells (1) stress and anxiety questionnaire (1) supportive and symptomatic treatment (1) surveys and questionnaires (1) suspected of COVID-19 infection (1) sweat samples (COVIDOG ancillary study) (1) systemic treatment (1) tacrolimus (1) teleconsultation (1) telehealth applications (1) telemedicine (1) telephone consult (1) telmisartan 40 mg/amlodipine 5 mg (1) telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg (1) telmisartan 40 mg/indapamide 2.5 mg (1) thalidomide (1) therapeutic plasmaexchnage (1) theraputic heparin (1) this study is non- interventional (1) thoracic CT-scan (1) thoracic computed tomography scan (1) thoracic lung ultrasound (1) thromboprofylaxis protocol (1) thromboprophylaxis with low-molecular-weight heparin or fondaparinux (1) thymosin alpha 1 (1) topical steroids and cyclosporin-A (1) tracheostomy (1) traditional communication tools (1) transparent sheet (1) treated with hyperimmune plasma (1) turkish physicians (1) unfractionated heparin (1) urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic (1) use and exposure to disinfectants during the coronavirus pandemic (1) vaccine (1) vaccine BCG (1) vaccine candidate MVA-MERS-S (1) vadadustat (1) venipuncture in peripheral vein (1) ventilatory support with oxygen therapy (1) virgin coconut oil (VCO) (1) vitamin D (1) vitamin d (1) von Willebrand factor (Recombinant) (1) vv-ECMO (1) washed microbiota transplantation (1) web based survey (1) wedged insole (1) zinc (1) zinc gluconate and ascorbic acid (1) ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. (1) γ-Globulin (1) Оxygen therapy (1)

    Ivermectin

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (59)


    Name (Synonyms) Correlation
    drug467 BI 730357 Wiki 0.21
    drug4116 Two doses of placebo at the routine vaccination schedule Wiki 0.21
    drug1316 EP Wiki 0.21
    Name (Synonyms) Correlation
    drug4104 Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki 0.21
    drug3184 Quantitative analysis of anti-SARS-CoV-2-antibodies Wiki 0.21
    drug2557 Nitazoxanide with ivermectin Wiki 0.21
    drug805 CT-scan Wiki 0.21
    drug4115 Two doses of placebo at the emergency vaccination schedule Wiki 0.21
    drug1500 FX06 Wiki 0.21
    drug3506 Saline containing 1% Human serum albumin(solution without UC-MSCs) Wiki 0.21
    drug352 Artesunate Wiki 0.21
    drug2107 Lasix® Wiki 0.21
    drug3197 Questionnaire for evaluation of confinement on deviant sexual fantasies Wiki 0.21
    drug795 CRESTOR® Wiki 0.21
    drug3130 Proxalutamide Wiki 0.21
    drug3858 T89 Wiki 0.21
    drug4105 Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki 0.21
    drug4109 Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki 0.21
    drug242 Albendazole Wiki 0.21
    drug347 Artemesia annua Wiki 0.21
    drug2850 Pegylated Interferon-α2b Wiki 0.21
    drug2971 Placebo of FX06 Wiki 0.21
    drug4617 non-interventional Wiki 0.21
    drug4110 Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki 0.21
    drug3159 Pulse oximetry Wiki 0.21
    drug2116 Lenoxin® Wiki 0.21
    drug1750 Home-based exercise Wiki 0.21
    drug4800 vadadustat Wiki 0.21
    drug2048 Ivermectin wth chloroquine Wiki 0.21
    drug1288 Dutasteride Wiki 0.21
    drug1266 Doxycycline Hcl Wiki 0.21
    drug2869 Peripheral blood sampling Wiki 0.21
    drug2356 MetfoLiquid GeriaSan® Wiki 0.21
    drug1302 EEG Wiki 0.21
    drug3766 Standard treatment for COVID-19 Wiki 0.21
    drug1769 Humanistic Care Wiki 0.21
    drug904 Chloroquine Wiki 0.16
    drug1339 Eculizumab Wiki 0.15
    drug1564 Follow up Wiki 0.15
    drug3431 SARS-CoV-2 diagnostic rapid test Wiki 0.15
    drug1052 Convalescent Plasma Transfusion Wiki 0.15
    drug617 Blood tests Wiki 0.15
    drug2560 Nitric Oxide Gas Wiki 0.12
    drug918 Cholecalciferol Wiki 0.11
    drug1959 Interferon Beta-1A Wiki 0.11
    drug421 Azithromycin Wiki 0.10
    drug4122 UC-MSCs Wiki 0.10
    drug1265 Doxycycline Wiki 0.10
    drug4253 Vitamin D3 Wiki 0.09
    drug1127 DAS181 Wiki 0.09
    drug4335 Zinc Wiki 0.08
    drug832 Camostat Mesilate Wiki 0.08
    drug2176 Losartan Wiki 0.07
    drug2916 Placebo Wiki 0.06
    drug1775 Hydroxychloroquine Wiki 0.06
    drug4249 Vitamin C Wiki 0.06
    drug4650 placebo Wiki 0.06
    drug2552 Nitazoxanide Wiki 0.06
    drug3728 Standard of Care Wiki 0.03

    Correlated MeSH Terms (21)


    Name (Synonyms) Correlation
    D014257 Trichuriasis NIH 0.21
    D011470 Prostatic Hyperplasia NIH 0.21
    D006965 Hyperplasia NIH 0.21
    Name (Synonyms) Correlation
    D006373 Helminthiasis NIH 0.21
    D000505 Alopecia NIH 0.15
    D000073296 Noncommunicable Diseases NIH 0.15
    D018352 Coronavirus Infections NIH 0.12
    D001927 Brain Diseases NIH 0.10
    D045169 Severe Acute Respiratory Syndrome NIH 0.09
    D003327 Coronary Disease NIH 0.08
    D050177 Overweight NIH 0.07
    D007239 Infection NIH 0.07
    D006331 Heart Diseases NIH 0.06
    D003141 Communicable Diseases NIH 0.05
    D013577 Syndrome NIH 0.04
    D002318 Cardiovascular Diseases NIH 0.04
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
    D055371 Acute Lung Injury NIH 0.04
    D011014 Pneumonia NIH 0.03
    D012128 Respiratory Distress Syndrome, Adult NIH 0.03
    D014777 Virus Diseases NIH 0.02

    Correlated HPO Terms (5)


    Name (Synonyms) Correlation
    HP:0008711 Benign prostatic hyperplasia HPO 0.21
    HP:0002293 Alopecia of scalp HPO 0.15
    HP:0001298 Encephalopathy HPO 0.10
    Name (Synonyms) Correlation
    HP:0001626 Abnormality of the cardiovascular system HPO 0.04
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 22 clinical trials


    1 Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients

    There are four species of intestinal worms collectively known as soil-transmitted helminthiasis (STH): Ancylostoma duodenale and Necator americanus (hookworms), Ascaris lumbricoides (roundworms), and Trichuris trichiura (whipworms). These parasites affect over two billion people and contribute to significant morbidity and disability, especially in high risk groups, for example children, agricultural workers and pregnant women. In children, STH are associated with impaired nutritional status evidenced by stunting, thinness and underweight. As is the case in most Latin America, STH are a public health problem in Honduras. The World Health Organization (WHO) informs that more than 2.5 million children (under 15 years of age) in the country are at risk of infection. To control these infections Honduras has established a national deworming program that operates since 2001 but despite these efforts, the prevalence of STH infections remains unacceptably high. This is especially true in rural communities where prevalence can be as high as 70% of the children population. Ivermectin (IVM) in combination with albendazole (ALB) has demonstrated the capacity to improve efficacy compared to any of these drugs in monotherapy; the efficacy is however, still inadequate in terms of cure rate, although egg reduction rates are significant. The purpose of the current trial is to assess the safety and efficacy of 3 experimental regimens for the treatment of infections by Trichuris trichiura in children in comparison with the current standard of practice in Mass Drug Administration (MDA) campaigns. The experimental regimens will explore the effect of multiple day regimens and high dose ivermectin. Treatment arms: - Group 1: single dose of ALB 400 mg. (active control arm). N:39 - Group 2: single dose ALB 400mg + IVM 600µg/Kg. N: 57 - Group 3: daily dose ALB 400mg for 3 consecutive days. N:24 - Group 4: daily dose ALB 400mg + IVM 600µg for 3 consecutive days. N:57 Total Study Population: 177

    NCT04041453
    Conditions
    1. Trichuris Infection
    2. Helminthiasis
    Interventions
    1. Drug: Ivermectin
    2. Drug: Albendazole
    MeSH:Helminthiasis Trichuriasis

    Primary Outcomes

    Description: Number of individuals cured from Trichuris trichiura infection using the duplicate Kato Katz laboratory method on a single sample of fresh stools as the measurement tool. Cure rate is defined as the absence of Trichuris trichiura eggs in post-treatment samples.

    Measure: Cure Rate

    Time: 21 days

    Secondary Outcomes

    Description: Calculation details: 100 x (1 - arithmetic mean fecal egg count post-intervention / arithmetic mean fecal egg count pre-intervention) Egg change rate was calculated across all participants, as described in reference: Levecke B et al., PLoS Negl Trop Dis. 2014;8(10).

    Measure: Egg Change Rate

    Time: 21 days

    Description: Measurement of the incidence of mutations of tubulin in Trichuris trichiura eggs collected pre and post treatment using molecular biology techniques. This data is not available yet due to the COVID-19 pandemic, but the data will be available and reported in the future. Anticipated reporting date for this outcome measure is estimated by 2021 and will be confirmed once the pandemic is over.

    Measure: Beta Tubulin Resistance

    Time: 21days
    2 Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment

    Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment

    NCT04351347
    Conditions
    1. COVID
    Interventions
    1. Drug: Ivermectin
    2. Drug: Nitazoxanide with ivermectin
    3. Drug: Ivermectin wth chloroquine

    Primary Outcomes

    Description: The number of patients with improvement or death

    Measure: Number of patients with improvement or died

    Time: 1 month
    3 To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study

    At present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.

    NCT04373824
    Conditions
    1. COVID
    Interventions
    1. Drug: Ivermectin

    Primary Outcomes

    Description: Test for virus at 1, 3 & 5 days from beginning of trial drug started for the patient in the hospital

    Measure: effect of Ivermectin on eradication of virus.

    Time: 3 months
    4 Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients

    This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.

    NCT04374019
    Conditions
    1. COVID
    2. Sars-CoV2
    Interventions
    1. Drug: Ivermectin
    2. Drug: Camostat Mesilate
    3. Dietary Supplement: Artemesia annua
    4. Drug: Artesunate

    Primary Outcomes

    Description: Proportion of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.

    Measure: Clinical Deterioration

    Time: 14 days

    Secondary Outcomes

    Description: The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.

    Measure: Change in Viral Load

    Time: 40 days

    Description: Percentage of patients that experience severe respiratory or other organ failure.

    Measure: Rate of Organ Failure

    Time: 28 days

    Description: Percentage of patients requiring ICU admission or ventilation.

    Measure: Progression to ICU Care or Ventilation

    Time: 28 days

    Description: Clinical status will be assessed using the COVID 7-Point Ordinal Outcomes Scale. This scale ranges from 1-7. Lower scores indicate worse outcomes; higher scores indicate fewer symptoms and better outcomes.

    Measure: Change in Clinical Status

    Time: 14 days

    Description: Percentage of patients who have died by day 14.

    Measure: Mortality

    Time: 14 days

    Description: Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.

    Measure: Rate of severe adverse events

    Time: 14 days

    Description: Number of days patients do not require oxygen supplementation.

    Measure: Oxygen-free days

    Time: 28 days

    Description: Number of days patients do not require mechanical ventilation.

    Measure: Ventilator-free days

    Time: 28 days

    Description: Number of days patients do not require vasopressor treatment.

    Measure: Vasopressor-free days

    Time: 28 days

    Description: Number of days patients do not require ICU services.

    Measure: ICU-free days

    Time: 28 days

    Description: Number of days patients do not require hospitalization.

    Measure: Hospital-free days

    Time: 28 days

    Description: Proportion of patients meeting Hy's law criteria.

    Measure: Patients meeting Hy's Law criteria

    Time: 28 days

    Description: Proportion of patients with changes in the following liver function tests: Any ALT or AST ≥ 5 x ULN; any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the ULN); Persistent ALT ≥ 3 x ULN for a period of more than 4 weeks

    Measure: Liver Function

    Time: 28 days

    Description: Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms.

    Measure: Heart Function

    Time: 28 days
    5 Novel Treatment Regimens in Treatment of COVID-19

    Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

    NCT04382846
    Conditions
    1. COVID
    2. Corona Virus Infection
    Interventions
    1. Drug: Nitazoxanide
    2. Drug: Ivermectin
    3. Drug: Chloroquine
    4. Drug: Azithromycin
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: the number of patients with virological cure

    Measure: Number of patients with virological cure

    Time: 6 months
    6 Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

    We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?

    NCT04384458
    Conditions
    1. Coronavirus Infections
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Ivermectin
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Proportion of participants in whom there was a a positivity for SARS-CoV-2 through specific examination (RT-PCR) or by serology for antibodies specific (IgM and IgG), corroborated or not with clinical finding of COVID-19, defined as the occurrence of signs and symptoms suggestive of this disease.

    Measure: Proportion of participants in whom there was a positivity for SARS-CoV-2.

    Time: Post-intervention at day 52

    Secondary Outcomes

    Description: Proportion of participants who developed mild, moderate, or severe forms of COVID-19.

    Measure: Participants who developed mild, moderate, or severe forms of COVID-19.

    Time: Post-intervention at day 52.

    Description: Measurement of the QT interval through electrocardiogram evaluation.

    Measure: Measurement of the QT interval.

    Time: Baseline, 3, 15 and 45 days post-intervention.

    Description: Proportion of participants who evolved with widening of the corrected QT interval or with changes in heart rate on the ECG.

    Measure: Widening of the corrected QT interval or with changes in heart rate on the ECG.

    Time: Day 52.

    Description: Comparison of baseline (visit 0) and final (visit 5) values of hematological and biochemical parameters.

    Measure: Comparison of hematological and biochemical parameters.

    Time: Day 52.

    Description: Proportion of occurrence of adverse events reported by participants or verified by the attending physician, or even observed in laboratory tests.

    Measure: Occurrence of adverse events.

    Time: Post-intervention at day 52.

    Description: Severity of symptoms of COVID-19 measured by a visual analog scale (VAS), with scores ranging from zero to 10, where zero represents the absence of the symptom and 10 corresponds to the most intense manifestation of symptoms (severe dyspnoea).

    Measure: Assessment of COVID-19 symptom severity.

    Time: Post-intervention at day 52.

    Description: Proportion of participants who discontinue study intervention,

    Measure: Proportion of participants who discontinue study intervention.

    Time: Post-intervention at day 52.

    Description: Proportion of participants who required hospital care.

    Measure: Proportion of participants who required hospital care.

    Time: Post-intervention at day 52.

    Description: Proportion of participants who required mechanical ventilation.

    Measure: Proportion of participants who required mechanical ventilation.

    Time: Post-intervention at day 52.
    7 Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission

    SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.

    NCT04390022
    Conditions
    1. Covid-19
    2. Coronavirus Infection
    3. SARS-CoV-2 In
    4. SARS-CoV-2 Infection
    Interventions
    1. Drug: Ivermectin
    2. Drug: Placebo
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment

    Measure: Proportion of patients with a positive SARS-CoV-2 PCR

    Time: 7 days post-treatment

    Secondary Outcomes

    Description: Change from baseline quantitative and semi-quantitative PCR in nasopharyngeal swab

    Measure: Mean viral load

    Time: Baseline and on days 4, 7, 14 and 21

    Description: Proportion of patients with fever and cough at days 4, 7, 14 and 21 as well as proportion of patients progressing to severe disease or death during the trial

    Measure: Fever and cough progression

    Time: Up to and including day 21

    Description: Proportion of participants with positive IgG at day 21

    Measure: Seroconversion at day 21

    Time: Up to and including day 21

    Description: Proportion of drug-related adverse events

    Measure: Proportion of drug-related adverse events

    Time: 7 days post treatment

    Description: Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay

    Measure: Levels of IgG, IgM and IgA

    Time: Up to and including day 28

    Description: Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry

    Measure: Frequency of innate immune cells

    Time: Up to and including day 7

    Description: Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry

    Measure: Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells

    Time: Up to and including day 7

    Description: Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher)

    Measure: Results from cytokine Human Magnetic 30-Plex Panel

    Time: Up to and including day 28
    8 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial

    Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.

    NCT04391127
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Ivermectin
    3. Drug: Placebo
    MeSH:Infection

    Primary Outcomes

    Description: Days from admission as a suspected case of COVID with hospitalization criteria until discharge

    Measure: Mean days of hospital stay

    Time: Three months

    Description: Respiratory deterioration defined by respiratory rate > 25 per minute, requirement of high oxygen supply (FiO2 > 80% ) to maintain oxygen saturation > 90 %, invasive mechanical ventilation or dead.

    Measure: Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead

    Time: Three months

    Description: Daily delta of oxygenation index during the hospitalization

    Measure: Mean of oxygenation index delta

    Time: Three months

    Secondary Outcomes

    Description: Mean time to viral negativization of RT-qPCR SARS-CoV-2. Pre Specified time: 5, 14, 21 and 28 days after the first positive PCR.

    Measure: Mean time to viral PCR negativization

    Time: 5, 14, 21 and 28 days after the first positive PCR
    9 A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol

    As the world faces COVID-19, the search for effective treatments against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase serum concentration of 25-hydroxyvitamin D.

    NCT04399746
    Conditions
    1. COVID
    Interventions
    1. Drug: Ivermectin
    2. Drug: Azithromycin
    3. Drug: Cholecalciferol

    Primary Outcomes

    Description: Test for virus at day 1 and 14 from beginning of trial drug started

    Measure: Viral clearance

    Time: 14 days

    Secondary Outcomes

    Description: The duration of symptoms in days

    Measure: Symptoms duration

    Time: 14 days

    Description: oxygen saturation

    Measure: SpO2

    Time: 14 days

    Description: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio

    Measure: SpO2/FiO2

    Time: 14 days
    10 The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment

    Efficacy of Ivermectin and Doxycycline in COVID-19 treatment

    NCT04403555
    Conditions
    1. COVID
    Interventions
    1. Drug: Ivermectin
    2. Drug: Doxycycline
    3. Drug: Chloroquine

    Primary Outcomes

    Description: The number of patients with improvement or mortality

    Measure: The number of patients with improvement or mortality

    Time: 1 month
    11 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

    This study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus disease (COVID-19). The primary efficacy endpoint is the proportion of participants with a disease control status defined as no progression of severe disease Hypothesis (H0): There is no difference between group A (ivermectin + paracetamol) and group B (ivermectin + paracetamol) in terms of the primary endpoint on day 14.

    NCT04407507
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Ivermectin
    2. Drug: Placebo

    Primary Outcomes

    Description: The subject is considered to have progressed to severe illness when one or more of the following criteria are present: Breathing difficulty (≥30 breaths per minute); Resting oxygen saturation ≤93%; Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.

    Measure: Participants with a disease control status defined as no disease progression to severe.

    Time: 14 days
    12 The Use of Ivermectin In the Treatment of COVID 19 Patients

    as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

    NCT04425707
    Conditions
    1. Covid19
    Interventions
    1. Drug: Ivermectin

    Primary Outcomes

    Description: the role of ivermectin in the cure of COVID 19 patients

    Measure: to evaluate the role of Ivermectin as a line of treatment for COVID 19

    Time: 2 months

    Secondary Outcomes

    Description: to compare the results of ivermectin with the standard care

    Measure: To asses the rate of viral clearance in comparison to other treatment protocols.

    Time: 2 months
    13 Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)

    In December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.

    NCT04431466
    Conditions
    1. Coronavirus Infection
    Interventions
    1. Drug: Ivermectin
    2. Other: Standard treatment for COVID-19
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab after Intervention Initiation.

    Measure: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.

    Time: 7 days following intervention

    Secondary Outcomes

    Description: Viral load variation in the nasopharyngeal swab during treatment.

    Measure: Viral load variation in the nasopharyngeal swab.

    Time: 7 days following intervention.

    Description: Variation of serum lymphocyte counts during treatment.

    Measure: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.

    Time: 7 days following intervention.

    Description: Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab at the end of follow-up.

    Measure: Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.

    Time: 7 after intervention.

    Description: Proportion of patients with clinical improvement, defined as the time to normalize fever, respiratory rate and oxygen saturation and cough relief at the end of follow-up.

    Measure: Proportion of patients with clinical improvement.

    Time: 7 after intervention.
    14 Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19

    Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection. Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres. In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.

    NCT04438850
    Conditions
    1. Covid19
    Interventions
    1. Drug: Ivermectin
    2. Other: Placebo

    Primary Outcomes

    Description: Number of serious adverse drug reaction

    Measure: SADR

    Time: 14 days

    Description: Quantitative viral load as measured by quantitative, digital droplet PCR.

    Measure: Viral load

    Time: Assessed at day 7

    Secondary Outcomes

    Description: 1. Trend over time of quantitative viral load at Day 7 and 14 as measured by quantitative, digital droplet PCR.

    Measure: Trend viral load

    Time: Days 7 and 14 from baseline

    Description: Time to clinical resolution (for symptomatic patients).

    Measure: Clinical resolution

    Time: Assessed on Day 30

    Description: Time from diagnosis to documented viral clearance

    Measure: Viral clearance

    Time: assessed on days 14 and 30

    Description: Proportion of patients with virological clearance

    Measure: Virological clearance

    Time: Assessed at day 14 and 30

    Description: rate of hospitalization

    Measure: hospitalization rate

    Time: Day 30

    Description: COVID-19 Severity Score (Coronavirus Diseases 19 Severity Score) - min value 1 ("no limitation of activities), max value 8 ("death"). Higher scores mean worse outcome

    Measure: Severity score

    Time: Assessed at Day 14 and Day 30
    15 Use of Ivermectin as a Therapeutic Option for Patients With COVID-19

    confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

    NCT04445311
    Conditions
    1. COVID
    Interventions
    1. Drug: Ivermectin

    Primary Outcomes

    Description: duration from day 1 symptoms till 3 days without symptoms

    Measure: time to be symptoms free

    Time: within 21 days after enrollment

    Secondary Outcomes

    Description: need hospital admission

    Measure: hospitalization

    Time: within 21 days after enrollement

    Description: need mechanical ventilation

    Measure: Mechanical ventilation

    Time: within 21 days after enrollement

    Description: days spent in hospital

    Measure: length of stay

    Time: within one month days after enrollement

    Description: survived or died

    Measure: mortality

    Time: within one month days after enrollement
    16 Anti-Androgen Treatment for COVID-19

    This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

    NCT04446429
    Conditions
    1. COVID-19
    2. SARS-CoV2
    3. Androgenetic Alopecia
    4. Prostate Cancer
    5. Benign Prostatic Hyperplasia
    6. SARS (Severe Acute Respiratory Syndrome)
    Interventions
    1. Drug: Dutasteride
    2. Drug: Ivermectin
    3. Drug: Azithromycin
    4. Drug: Proxalutamide
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Prostatic Hyperplasia Alopecia Hyperplasia
    HPO:Alopecia Alopecia of scalp Benign prostatic hyperplasia Frontal balding

    Primary Outcomes

    Description: Percentage of subjects hospitalized due to COVID-19

    Measure: COVID-19 hospitalization

    Time: 30 days

    Description: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

    Measure: COVID-19 Ordinal Outcomes Scale

    Time: 30 days

    Secondary Outcomes

    Description: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm

    Measure: Symptoms severity of COVID-19

    Time: 30 days
    17 Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19

    Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19

    NCT04447235
    Conditions
    1. Cancer
    2. COVID
    3. Coronavirus Infection
    Interventions
    1. Drug: Placebo
    2. Drug: Ivermectin
    3. Drug: Losartan
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Incidence of severe complications due COVID-19 infection defined as need for ICU admission, need for mechanical ventilation, or death

    Measure: Incidence of severe complications due COVID-19 infection

    Time: 28 days

    Secondary Outcomes

    Description: Severe Acute Respiratory Syndrome defined as oxygen saturation less than 93%

    Measure: Incidence of Severe Acute Respiratory Syndrome

    Time: 28 days

    Description: Severe Acute Respiratory Syndrome defined as respiratory rate higher than 24 incursion per minute

    Measure: Incidence of Severe Acute Respiratory Syndrome

    Time: 28 days

    Description: Incidence of hepatic toxicity (elevation of ALT, AST above the upper limit of normal, measured by U/L)

    Measure: Adverse events

    Time: 28 days

    Description: Incidence of hepatic toxicity (elevation of bilirubin above the upper limit of normal, measured by mg/dL)

    Measure: Adverse events

    Time: 28 days

    Description: Incidence of renal toxicity (elevation of serum creatinine levels above the upper limit of normal, measured by mg/dL)

    Measure: Adverse events

    Time: 28 days

    Description: Incidence of symptomatic postural hypotension, diagnosed by clinical assessment of reduction of > 20 mmHG of arterial systolic pressure after measurement in prone position and orthostatic position.

    Measure: Adverse events

    Time: 28 days

    Description: Death of any cause since protocol enrollment

    Measure: Overall survival

    Time: 28 days
    18 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study

    On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

    NCT04460547
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Convalescent Plasma Transfusion
    2. Drug: Hydroxychloroquine
    3. Drug: DAS181
    4. Drug: Ivermectin
    5. Drug: Interferon Beta-1A

    Primary Outcomes

    Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.

    Measure: Geographical distribution of the interventional studies after 11th of March 2020.

    Time: 15th of August 2020

    Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.

    Measure: Geographical distribution of the Observational studies after 11th of March 2020.

    Time: 15th of August 2020

    Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.

    Measure: Monthly Research study completion rate as per geographic distribution of the Research.

    Time: 15th of August 2020

    Secondary Outcomes

    Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020

    Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

    Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

    Time: 15th of August 2020
    19 A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection

    In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.

    NCT04482686
    Conditions
    1. COVID
    2. Covid-19
    3. Corona Virus Infection
    4. Coronavirus Infection
    5. Coronavirus-19
    6. SARS-CoV2
    7. SARS-CoV Infection
    Interventions
    1. Drug: Ivermectin
    2. Drug: Doxycycline Hcl
    3. Dietary Supplement: Zinc
    4. Dietary Supplement: Vitamin D3
    5. Dietary Supplement: Vitamin C
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Time to negative RT-PRC result indicating that patient is no longer infective

    Measure: Time to Non-Infectivity by RT-PCR

    Time: 6 months

    Description: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.

    Measure: Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)

    Time: 6 months

    Description: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.

    Measure: Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)

    Time: 6 months

    Description: Patients will have serum stored for titer testing to compare antibody levels over time

    Measure: Efficacy of Treatment as measured by Titer

    Time: 6 months

    Description: Number of patients testing negative for SARS-CoV-2 by RT-PCR after 10 days of treatment

    Measure: Efficacy of Treatment as measured by RT-PCR

    Time: 10 days

    Secondary Outcomes

    Description: Blood D-Dimer levels

    Measure: Safety of Treatment as Measured by D-Dimer

    Time: 6 Months

    Description: Blood Pro-Calcitonin levels

    Measure: Safety of Treatment as Measured by Pro-Calcitonin

    Time: 6 Months

    Description: Blood CRP levels

    Measure: Safety of Treatment as Measured by C-Reactive Protein

    Time: 6 Months

    Description: Blood ferritin levels

    Measure: Safety of Treatment as Measured by Ferritin

    Time: 6 Months

    Description: Blood enzyme levels

    Measure: Safety of Treatment as Measured by Liver Enzymes

    Time: 6 Months

    Description: CBC

    Measure: Safety of Treatment as Measured by Complete Blood Count

    Time: 6 Months

    Description: Blood electrolytes

    Measure: Safety of Treatment as Measured by Electrolyte Levels

    Time: 6 Months

    Description: Presence or absence of Grade 3 or high treatment related adverse events

    Measure: Safety of Treatment as Measured by Treatment Related Adverse Events

    Time: 6 months
    20 Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic: A Randomized Clinical Controled Trial

    It will be performed a randomized, multicenter, triple-masked, placebo-controlled clinical experiment to determine the effectiveness and safety of the administration to of ivermectin at a dose of 200 mcg/kg once a week for 7 weeks in a prophylactic treatment against SARS COV-2 infection in 550 Colombian health workers during the COVID-19 pandemic.

    NCT04527211
    Conditions
    1. Covid19
    2. Healthcare Worker Patient Transmission
    Interventions
    1. Drug: Ivermectin
    MeSH:Infection

    Primary Outcomes

    Description: Development of of the disease according to the definitions of cases found in the guidelines from the Colombian National Institute of Health

    Measure: Clinical development of covid-19 disease during the intervention period

    Time: 8 weeks

    Secondary Outcomes

    Description: Indicate if the patient had positive serological antibodies at the end of the study

    Measure: Seroconversion

    Time: 8 weeks

    Description: Need for hospitalization independent of the level of complexity due to covid-19

    Measure: Hospitalization requirement

    Time: 8 weeks

    Description: ICU need due to Covid-19

    Measure: Intensive Care Unit Requirement

    Time: 8 weeks

    Description: Adverse effect due to medication or placebo

    Measure: Safety of the intervention

    Time: 8 weeks
    21 Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled

    It is a single-center, prospective, randomized, double-blind, placebo-controlled study carried out by the Ministry of Public Health of the Province of Corrientes, Argentina, in coordination with the Corrientes Institute of Cardiology "Juana F. Cabral". Patients who meet all the inclusion criteria and none of the exclusion criteria are randomized via the web system to receive placebo or ivermectin. The need for hospitalization in patients with COVID-19 is assessed as the primary end point. As secondary end points are evaluated: time to hospitalization (in days); use of invasive mechanical ventilation; time to invasive mechanical ventilation (in days); dialysis; all-cause mortality; negative of the swab at 3 ± 1 days and 12 ± 2 days after entering the study and ivermectin safety. Intermediate internal analyzes of study objectives and serious adverse events will be performed, including 125; 250 and 375 patients in order to assess the possible need for early termination of the study. For these intermediate internal analyzes, the Haybittle-Peto rule will be followed, therefore a value of p <0.001 will be considered significant

    NCT04529525
    Conditions
    1. Covid19
    Interventions
    1. Drug: Ivermectin
    2. Drug: Placebo

    Primary Outcomes

    Description: Hospitalization will be considered when at least 24 hours have elapsed in a health institution, in any of its services.

    Measure: Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm

    Time: through study completion, an average of 30 days

    Secondary Outcomes

    Description: Number of days elapsed

    Measure: Time to hospitalization

    Time: through study completion, an average of 30 days

    Description: All patients who are connected to invasive mechanical ventilation support

    Measure: Percentage of Use of invasive mechanical ventilation support in each arm

    Time: through study completion, an average of 30 days

    Description: Number of days elapsed

    Measure: Time to invasive mechanical ventilation support

    Time: through study completion, an average of 30 days

    Description: All patients who require temporary or permanent renal replacement therapy

    Measure: Percentage of dialysis in each arm

    Time: through study completion, an average of 30 days

    Description: Death of the patient, from any cause.

    Measure: All-cause mortality

    Time: through study completion, an average of 30 days

    Description: Negative Nasal Swab Using Polymerase Chain Reaction Technique

    Measure: Negative of the swab at 3±1 days and 12±2 days after entering the study

    Time: At days 3±1 and 12±2

    Description: According to the adverse events that patients may present.

    Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

    Time: through study completion, an average of 30 days
    22 Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial

    Since the onset of the disease, more than 40.5 million people have been diagnosed with COVID-19 and nearly 1.2 million people have died (October 21, 2020). There is no complete understanding of the pathogenesis of SARS-CoV-2 infection and to this day there is no specific therapy or vaccine available. Thus, patient care is based on symptomatic therapy and treatment of complications. Ivermectin has been used for more than 30 years for the treatment of several diseases. More than one million doses of the drug are administered daily, particularly in low- and middle-income countries. Due to the low prevalence of adverse events with the use of this drug, ivermectin is considered to have a good safety profile and its potential benefit in other diseases is currently under investigation. An in vitro study of ivermectin in SARS-CoV-2 in Australia showed a significant reduction of viral load in infected cells. Subsequently, a descriptive study of 704 critical patients with COVID-19 showed a reduction in mortality, hospitalization, and intensive care unit length-of-stay in those patients who received the drug. Unfortunately, this study was withdrawn by its authors, leaving more questions than answers. Some countries in Latin America have authorized its use for the management of patients with COVID-19 even in the absence of solid evidence, and several other countries are conducting clinical trials to evaluate its efficacy for the treatment of moderate and severe disease. Since there is no specific treatment for COVID-19 and the therapeutic options are scarce, the researchers believe it is completely plausible, urgent, and necessary to evaluate if ivermectin use reduces the risk of admission to an intensive care unit (ICU) in hospitalized adults with severe COVID-19. The proposal is a randomized, double-blind clinical trial, conducted at CES Clinic, Medellin-Colombia. The investigators will randomize 100 patients with severe, non-critical illness, into two groups, one group will receive ivermectin in addition to standard management and the other group will receive placebo plus standard management. Clinical outcomes to evaluate will be ICU admission, need for mechanical ventilation, length of hospital stay, days in the ICU and mechanical ventilation, and finally, the incidence of adverse events related to the intervention. The estimated time to complete the study is approximately five months.

    NCT04602507
    Conditions
    1. Covid19
    2. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Ivermectin
    2. Other: Placebo
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: Cumulative incidence of ICU admission.

    Measure: Admission to the intensive care unit.

    Time: 21 days

    Secondary Outcomes

    Description: Duration of hospitalization (days).

    Measure: Hospital length of stay.

    Time: 21 days

    Description: 21-day mortality.

    Measure: Mortality rate.

    Time: 21 days

    Description: Number of days in ICU.

    Measure: ICU length of stay.

    Time: 21 days

    Description: Number of days with mechanical ventilator.

    Measure: Length of stay in ventilator time.

    Time: 21 days

    Description: Cumulative incidence of adverse effects: headache, rash, pruritus, arthralgia, tachycardia, dizziness, hypotension, uveitis, Steven Johnson Syndrome.

    Measure: Adverse effects of ivermectin.

    Time: 21 days

    Related HPO nodes (Using clinical trials)


    HP:0001596: Alopecia
    Genes 288
    DCLRE1C TGM3 LSS RECQL4 HFE ECM1 FOXN1 NFKB2 DLL4 RBM28 NRAS PNPLA6 DDB2 RNU4ATAC ALOXE3 SLC39A4 GJB2 LAMA3 BCS1L HR NIPAL4 SOX18 EDAR TARS1 MCCC2 SLC30A2 CHD7 TERT EDNRA TP63 STAT4 GJB6 LMNA MBTPS2 ALX4 LMNA FTL XPA OFD1 KRAS PLEC PERP ODC1 CD28 IKBKG ZMPSTE24 GJB6 ITGB4 BTD LAMC2 ATR SLC29A3 GTF2E2 KDM5C KRT74 ITGB4 ALOX12B HRAS HRAS CSTB DSP CTLA4 KRAS ABHD5 CTLA4 DVL3 LAMC2 TP63 BTD MBTPS2 ECM1 SPP1 PEX7 NSDHL TP63 KRT83 LPAR6 NECTIN1 ALOXE3 VDR HLA-DRA LMNA LMNA COL3A1 ERCC3 TRPV3 SNRPE MBTPS2 NHP2 COL18A1 HR KDSR RIN2 BCS1L AHSG SLITRK1 EPS8L3 PORCN KRT81 ABHD5 SMARCA2 KRT83 RAG2 ERCC3 DKC1 PNPLA1 DCAF17 CERS3 ZNF341 MPLKIP DSP FGFR1 FZD2 BMP2 EOGT KRT81 HR COL17A1 TINF2 CD28 TP63 GJB6 PARN ANTXR1 ABCD1 WRAP53 RPL21 ARHGAP31 HLCS AHSG UQCRFS1 GJA1 NPM1 AP1B1 ALMS1 GJB2 BLM PKP1 AIRE UBR1 AIRE FOXP3 NOTCH1 UROD ZMPSTE24 KRT86 COL17A1 IL2RA GJA1 IL2RG EBP KLHL24 PRKACA RAG2 MMP1 HLCS DSP TTC7A GJB3 NOP10 WNT10A ERCC2 FOXN1 KRT85 NRAS GNA11 DMXL2 ERCC5 GJB4 LAMA3 GJB2 MBTPS2 CTC1 MBTPS2 RBM28 DCLRE1C VDR AEBP1 KRT6B TGM1 ARHGAP31 LAMB3 IL7R ALX4 FGFR1 ERCC2 GJA1 TERC SLC39A4 LMNA KRT86 ITGB6 FLI1 SLC29A3 EPS8L3 MBTPS2 LAMB3 ALOX12B RAG1 EDARADD DCAF17 HFE EBP CLDN1 PADI3 TNFRSF1B PLEC CLDN1 STUB1 NFKB2 HTRA1 SNRPE APCDD1 SOX18 NECTIN4 OFD1 KRT16 KRAS TGM1 KRT17 MGP IRAK1 LSS FAM111B RTEL1 HFE PORCN DVL1 SOX18 TERC ACVR1 NFKB1 TNFRSF1B ACVR1 ANTXR1 LSS WNT10A KRT6A PIK3R1 KRT14 TINF2 RAG1 BTK UROS LMNA BTNL2 FOXP3 RMRP LIPH ZMPSTE24 TERT HR WNT5A RHOA TRPV3 COL7A1 RNF113A DOCK6 USB1 PARN SASH1 DKC1 RIPK4 ADA CASR TINF2 ROR2 DMPK DSG4 LIG4 DSG4 IL7R RIPK4 ERCC4 EXOSC2 JUP COL3A1 GTF2H5 TP63 ABCA12 NXN TGM1 IKBKG KDM5C HLA-DRB1 XPC PTPN22 RBPJ
    Protein Mutations 0
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    Related HPO nodes (Using clinical trials)


    HP:0001596: Alopecia
    Genes 288
    DCLRE1C TGM3 LSS RECQL4 HFE ECM1 FOXN1 NFKB2 DLL4 RBM28 NRAS PNPLA6 DDB2 RNU4ATAC ALOXE3 SLC39A4 GJB2 LAMA3 BCS1L HR NIPAL4 SOX18 EDAR TARS1 MCCC2 SLC30A2 CHD7 TERT EDNRA TP63 STAT4 GJB6 LMNA MBTPS2 ALX4 LMNA FTL XPA OFD1 KRAS PLEC PERP ODC1 CD28 IKBKG ZMPSTE24 GJB6 ITGB4 BTD LAMC2 ATR SLC29A3 GTF2E2 KDM5C KRT74 ITGB4 ALOX12B HRAS HRAS CSTB DSP CTLA4 KRAS ABHD5 CTLA4 DVL3 LAMC2 TP63 BTD MBTPS2 ECM1 SPP1 PEX7 NSDHL TP63 KRT83 LPAR6 NECTIN1 ALOXE3 VDR HLA-DRA LMNA LMNA COL3A1 ERCC3 TRPV3 SNRPE MBTPS2 NHP2 COL18A1 HR KDSR RIN2 BCS1L AHSG SLITRK1 EPS8L3 PORCN KRT81 ABHD5 SMARCA2 KRT83 RAG2 ERCC3 DKC1 PNPLA1 DCAF17 CERS3 ZNF341 MPLKIP DSP FGFR1 FZD2 BMP2 EOGT KRT81 HR COL17A1 TINF2 CD28 TP63 GJB6 PARN ANTXR1 ABCD1 WRAP53 RPL21 ARHGAP31 HLCS AHSG UQCRFS1 GJA1 NPM1 AP1B1 ALMS1 GJB2 BLM PKP1 AIRE UBR1 AIRE FOXP3 NOTCH1 UROD ZMPSTE24 KRT86 COL17A1 IL2RA GJA1 IL2RG EBP KLHL24 PRKACA RAG2 MMP1 HLCS DSP TTC7A GJB3 NOP10 WNT10A ERCC2 FOXN1 KRT85 NRAS GNA11 DMXL2 ERCC5 GJB4 LAMA3 GJB2 MBTPS2 CTC1 MBTPS2 RBM28 DCLRE1C VDR AEBP1 KRT6B TGM1 ARHGAP31 LAMB3 IL7R ALX4 FGFR1 ERCC2 GJA1 TERC SLC39A4 LMNA KRT86 ITGB6 FLI1 SLC29A3 EPS8L3 MBTPS2 LAMB3 ALOX12B RAG1 EDARADD DCAF17 HFE EBP CLDN1 PADI3 TNFRSF1B PLEC CLDN1 STUB1 NFKB2 HTRA1 SNRPE APCDD1 SOX18 NECTIN4 OFD1 KRT16 KRAS TGM1 KRT17 MGP IRAK1 LSS FAM111B RTEL1 HFE PORCN DVL1 SOX18 TERC ACVR1 NFKB1 TNFRSF1B ACVR1 ANTXR1 LSS WNT10A KRT6A PIK3R1 KRT14 TINF2 RAG1 BTK UROS LMNA BTNL2 FOXP3 RMRP LIPH ZMPSTE24 TERT HR WNT5A RHOA TRPV3 COL7A1 RNF113A DOCK6 USB1 PARN SASH1 DKC1 RIPK4 ADA CASR TINF2 ROR2 DMPK DSG4 LIG4 DSG4 IL7R RIPK4 ERCC4 EXOSC2 JUP COL3A1 GTF2H5 TP63 ABCA12 NXN TGM1 IKBKG KDM5C HLA-DRB1 XPC PTPN22 RBPJ
    Protein Mutations 0
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook